Document:

exv10w1

Exhibit 10.1

AMENDED AND RESTATED LICENSE AGREEMENT (2008)

This amended and restated agreement is between Biomira Management Inc., a Delaware corporation with
offices located at Seattle, Washington (“ONCOTHYREON”), and Merck KGaA, a German corporation with
offices located at Darmstadt, Germany (“MERCK”) and is effective as of December 18, 2008.

WHEREAS Biomira B.V. and MERCK entered into an amended and restated collaboration agreement
effective as of May 7, 2001 (the “2001 COLLABORATION AGREEMENT”) in relation to, inter alia, the
development of BLP25;

AND WHEREAS Biomira International Inc. and MERCK entered into an amended and restated supply
agreement effective as of May 7, 2001 (the “2001 SUPPLY AGREEMENT”) in relation to, inter alia, the
manufacture and supply by Biomira International Inc. to MERCK of BLP25;

AND WHEREAS the 2001 COLLABORATION AGREEMENT was further amended and restated by the parties
thereto by agreement effective as of March 1, 2006 (the “2006 COLLABORATION AGREEMENT”);

AND WHEREAS the 2001 SUPPLY AGREEMENT was further amended and restated by the parties thereto by
agreement effective as of March 1, 2006 (the “2006 SUPPLY AGREEMENT”);

AND WHEREAS on December 7, 2007, the respective rights and obligations of Biomira B.V. and Biomira
International Inc. under the 2006 COLLABORATION AGREEMENT and the 2006 SUPPLY AGREEMENT were
transferred and assigned to ONCOTHYREON;

AND WHEREAS ONCOTHYREON and MERCK now wish to combine and amend and restate the 2006 COLLABORATION
AGREEMENT and the 2006 SUPPLY AGREEMENT as a single amended and restated license agreement, all
upon the terms and subject to the conditions set forth in this AGREEMENT;

AND WHEREAS, ONCOTHYREON (and certain AFFILIATES of ONCOTHYREON) and EMD Serono Canada, Inc. (an
AFFILIATE of MERCK), in conjunction with entering into this AGREEMENT, have entered into an asset
purchase agreement (the “ASSET PURCHASE AGREEMENT”) pursuant to which ONCOTHYREON and the specified
AFFILIATES of ONCOTHYREON have sold certain assets relating to BLP25 to EMD Serono Canada, Inc.;

NOW, THEREFORE, in consideration of the premises and covenants contained herein and other good and
valuable consideration, the receipt and sufficiency of which is hereby agreed to by the parties,
and intending to be legally bound hereby, the parties hereto agree as follows:

ARTICLE 1

DEFINITIONS

Section 1.1 Meaning

Whenever a term is written in this AGREEMENT with all capital letters it shall have the following
meaning:

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

2

	 	1.1.1	 	“ADVERSE EVENT” means, with respect to PRODUCT in a particular country in the
TERRITORY, the occurrence of an adverse event with respect to PRODUCT as defined by
applicable law or regulation in such country;
	 
	 	1.1.2	 	“AFFILIATES” means any business entity that directly or indirectly controls,
is controlled by, or is under common control with either party to this AGREEMENT. A
business entity shall be deemed to “control” another business entity if it owns,
directly or indirectly, more than fifty (50%) percent of the outstanding voting
securities, capital stock, or other comparable equity or ownership interest of such
business entity. If the laws of the jurisdiction in which such business entity
operates prohibit ownership by a party of more than fifty percent (50%), control shall
be deemed to exist at the maximum level of ownership allowed by such jurisdiction;
	 
	 	1.1.3	 	“AGREEMENT” means this amended and restated license agreement, together with
all schedules and appendices hereto and any amendments to or restatements of this
amended and restated license agreement;
	 
	 	1.1.4	 	“ASSET PURCHASE AGREEMENT” has the meaning attributed to that term in the
seventh recital to this AGREEMENT;
	 
	 	1.1.5	 	“BLP25” means ONCOTHYREON’s immunotherapeutic vaccine composed of a 25-amino
acid sequence of the MUC1 cancer mucin, which vaccine is combined with the adjuvant
monophosphoryl Lipid A and is encapsulated in a liposomal delivery system, together
with (i) any IMPROVEMENTS thereto (such as liposomal IL-2 in a kit, synthetic Lipid A,
or new delivery formats such as unit dose liquid formulations and unit dose syringes)
owned by ONCOTHYREON or licensed in by ONCOTHYREON during the term of this AGREEMENT
with the right to sublicense in the manner contemplated by this AGREEMENT and (ii) any
PRODRUG thereof;
	 
	 	1.1.6	 	“BGLP40” means any variant of ONCOTHYREON’s (or its AFFILIATES’)
immunotherapeutic vaccine composed of two tandem repeats of the MUC1 cancer mucin,
whether or not glycosylated, and whether or not lapidated, which vaccine is combined
with an adjuvant and is encapsulated/incorporated in a liposomal delivery system,
together with any improvements thereto owned by ONCOTHYREON (or its AFFILIATES) or
licensed in by ONCOTHYREON (or its AFFILIATES);
	 
	 	1.1.7	 	“CLINICAL DEVELOPMENT” means all activities required for MARKET APPROVAL of
PRODUCT in the TERRITORY (including without limitation non-clinical and clinical
trials, including but not limited to, toxicology and absorption, distribution,
metabolism and elimination studies), as well as all clinical activities desirable for
optimized marketing of PRODUCT in the TERRITORY (including without limitation Phase
IIIb and Phase IV studies);

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

3

	 	1.1.8	 	“COMPETITIVE PRODUCT” means, with respect to PRODUCT in a particular country
in the ROW TERRITORY, a cancer vaccine developed, marketed and SOLD by a third party
(which, for greater certainty, shall exclude an AFFILIATE of a party to this AGREEMENT)
for the treatment and/or prevention of cancer that elicits a MUC1 specific immune
response (but excluding for greater certainty gene therapy products) and which has an
adverse impact on SALES of PRODUCT in such country;
	 
	 	1.1.9	 	“CONFIDENTIAL INFORMATION” has the meaning attributed to that term in section
8.1 of this AGREEMENT;
	 
	 	1.1.10	 	“CORE PATENT COUNTRIES” shall mean the countries listed in appendix 1;
	 
	 	1.1.11	 	“CORIXA LICENSE” means that certain adjuvant license agreement dated as of October
20, 2004 with Corixa Corporation, together with all schedules thereto and any
amendments to or restatements of such adjuvant license agreement;
	 
	 	1.1.12	 	“DANA-FARBER LICENSE” means that certain license agreement dated November 22, 1996
with the Dana-Farber Cancer Institute, Inc., together with all schedules thereto and
any amendments to or restatements of such license agreement;
	 
	 	1.1.13	 	“DEVELOPMENT PLAN” shall mean the development plans contemplated in section 3.1 of
this AGREEMENT;
	 
	 	1.1.14	 	“DISTRIBUTOR” means, with respect to PRODUCT in a particular country in the
TERRITORY, a third party retained to market, promote and/or sell PRODUCT in such
country, but excluding for greater certainty wholesalers and any such third party in
circumstances where the laws of such country require the use of such third party to
market, promote and/or sell PRODUCT in such country;
	 
	 	1.1.15	 	“DOMAIN NAMES” has the meaning attributed to that term in section 5.12.6 of this
AGREEMENT.
	 
	 	1.1.16	 	“EFFECTIVE DATE” shall mean December 18, 2008, or such other date as ONCOTHYREON and
MERCK may agree upon in writing;
	 
	 	1.1.17	 	“END USER” shall mean, with respect to PRODUCT, any person at arm’s length with MERCK
and its AFFILIATES that acquires PRODUCT in final form for end use, including
physicians and hospitals but excluding DISTRIBUTORS and other agents;
	 
	 	1.1.18	 	“FIELD” shall mean the use of BLP25 for the prevention and/or treatment of cancers in
humans;
	 
	 	1.1.19	 	“ICRT LICENSE” means that certain amended and restated license agreement dated
November 14, 2000 with Imperial Cancer Research Technology Limited

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

4

	 	 	 	(now Cancer Research Technology Limited), together with all schedules thereto and
any amendments to or restatements of such license agreement;
	 
	 	1.1.20	 	“IFRS” means international financial reporting standards, consistently applied;
	 
	 	1.1.21	 	“IMPROVEMENTS” means, collectively, all inventions, discoveries, improvements or
other technology in the FIELD and all processes or uses relating thereto, whether or
not patentable, that arise after the ORIGINAL EFFECTIVE DATE as a result of conduct
under this AGREEMENT and relate directly to BLP25. For clarity, IMPROVEMENTS shall not
include any inventions, discoveries, improvements or other technology that ONCOTHYREON,
develops or acquires to the extent covering any active compound that is separate and
clearly distinct from BLP25, notwithstanding the fact that such active compound may be
useful as part of a combination therapy with BLP25. For further clarity, BGLP40 shall
be deemed not to be an IMPROVEMENT;
	 
	 	1.1.22	 	“INDICATION” means a specific health care indication (e.g., non-small cell lung
cancer) for which PRODUCT is, as indicated on the label for the PRODUCT, specified for
the treatment and/or prevention thereof;
	 
	 	1.1.23	 	“JOINT IMPROVEMENT PATENT RIGHTS” has the meaning attributed to that term in section
10.1.1 of this AGREEMENT;
	 
	 	1.1.24	 	“JOINT IMPROVEMENTS” has the meaning attributed to that term in section 9.1 of this
AGREEMENT;
	 
	 	1.1.25	 	“LAUNCH” shall mean, with respect to PRODUCT in a particular country in the
TERRITORY, the date of the first arms’ length sale of PRODUCT in such country after
receipt of MARKET APPROVAL for PRODUCT in such country;
	 
	 	1.1.26	 	“MAJOR MARKET” shall mean any one of Germany, France, United Kingdom, Italy, Spain or
Japan, and “MAJOR MARKETS” shall mean all of such countries;
	 
	 	1.1.27	 	“MARKET APPROVAL” shall mean, with respect to PRODUCT in a particular country in the
TERRITORY, the date upon which the last of all governmental or regulatory approvals
required for the sale of PRODUCT in that country has been granted, including price
approval for the PRODUCT (if required);
	 
	 	1.1.28	 	“MARKETING PLAN” shall mean the marketing plans contemplated in section 3.1 of this
AGREEMENT;
	 
	 	1.1.29	 	“MERCK COST OF GOODS” includes, but is not limited to, with respect to PRODUCT in the
TERRITORY, reasonable direct material, labour and subcontracted costs incurred by or on
behalf of MERCK in connection with the procurement of raw materials, manufacture,
vialing, testing, stability, releasing and shipment of PRODUCT, as well as the
reasonable indirect costs of administration, salary, support, depreciation, facility
rental, facility repair and

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

5

	 	 	 	maintenance, facility utilities, insurance and facility property taxes attributable
to PRODUCT;
	 
	 	1.1.30	 	“MERCK IMPROVEMENTS” has the meaning attributed to that term in section 9.3 of this
AGREEMENT;
	 
	 	1.1.31	 	“MERCK MANUFACTURING ACTIVITIES” has the meaning attributed to that term in section
9.10 of this AGREEMENT;
	 
	 	1.1.32	 	“MERCK OFFER” has the meaning attributed to that term in section 2.7.2 of this
AGREEMENT;
	 
	 	1.1.33	 	“MUC1” means cancer associated mucin-1;
	 
	 	1.1.34	 	“NA TERRITORY” shall mean, collectively, Canada (including Quebec) and its
territories and the United States of America and its territories;
	 
	 	1.1.35	 	“NEGOTIATION PERIOD” has the meaning attributed to that term in section 2.7.2 of this
AGREEMENT;
	 
	 	1.1.36	 	“NET SALES” shall mean, with respect to PRODUCT in a particular country, the sum of
the gross amounts invoiced for all SALES (directly or indirectly) by MERCK, its
AFFILIATES and their respective sublicensees, DISTRIBUTORS, assignees and transferees
of PRODUCT to END USERS, less the following deductions from such invoiced amounts which
are actually incurred in accordance with IFRS:

	 	1.1.36.1	 	credits or allowances actually granted for spoiled or damaged PRODUCT or
with respect to returned or rejected PRODUCT, and for retroactive price
adjustments;
	 
	 	1.1.36.2	 	normal and customary trade, cash and quantity discounts, allowances,
rebates and credits actually allowed, including allowances, adjustments,
reimbursements, discounts, chargebacks and rebates given to healthcare
organizations and any governmental or quasi-governmental body or agency,
whether during the actual SALES/royalty period or not;
	 
	 	1.1.36.3	 	sales, value added or similar taxes measured by the billing amount, when
included in billing;
	 
	 	1.1.36.4	 	freight, postage, shipping, and insurance charges related to delivery of
PRODUCT from the applicable MERCK/distributor warehouse measured by the billing
amount, when included in billing; and
	 
	 	1.1.36.5	 	import and export duties actually paid.

Any refund or reimbursement of any of the foregoing amounts previously deducted from
NET SALES shall be appropriately credited upon receipt thereof.

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

6

If PRODUCT is SOLD in combination with another product or products (for greater
certainty the use of adjuvant or other such PRODUCT enhancer stipulated to be mixed
with PRODUCT shall not be considered to be “another product” for purposes of this
section 1.1.36), “NET SALES” under such circumstances shall be calculated by
multiplying the “NET SALES” of the combination by the fraction A/(A + B), in which A
is the amount invoiced for PRODUCT when SOLD separately, and B is the total amount
invoiced for any other product or products in combination when SOLD separately;

	 	1.1.37	 	“ONCOTHYREON IMPROVEMENTS” has the meaning attributed to that term in section 9.2 of
this AGREEMENT;

	 	1.1.38	 	“ONCOTHYREON KNOW-HOW” means all proprietary information and data in the FIELD
including but not limited to compounds, formulae, protocols, methods, techniques and
results of experimentation and testing, which, except for published patent applications
which are also included within this definition, is generally not known to the public,
and which are owned by ONCOTHYREON or licensed in by ONCOTHYREON with the right to
sublicense in the manner contemplated by this AGREEMENT, and which directly relate to
research, CLINICAL DEVELOPMENT, use and/or sale of PRODUCT and/or the manufacture of
PRODUCT. For greater certainty, ONCOTHYREON KNOW-HOW shall include ONCOTHYREON
IMPROVEMENTS and IMPROVEMENTS licensed in by ONCOTHYREON with the right to sublicense
in the manner contemplated by this AGREEMENT, which arise or occur after the ORIGINAL
EFFECTIVE DATE and which fall within the ambit of the preceding sentence.
Notwithstanding the foregoing, ONCOTHYREON KNOW-HOW shall not include any subsequently
developed or acquired ONCOTHYREON KNOW-HOW to the extent covering any active compound
that is separate and clearly distinct from PRODUCT, notwithstanding the fact that such
active compound may be useful as part of a combination therapy with PRODUCT;

	 	1.1.39	 	“ONCOTHYREON PATENT RIGHTS” means all rights in the FIELD owned by ONCOTHYREON or
licensed in by ONCOTHYREON with the right to sublicense in the manner contemplated by
this AGREEMENT in any of the following patents: any patent issuing on any patent
application identified in appendix 2, as well as any patent issuing from any continuing
applications of the patents listed in appendix 3, such applications including any
divisions, continuations, and continuation-in-part applications, as well as any patents
issuing on any reissue and/or reexamination application, and including any patent term
restoration or extension (i.e. supplemental protection certificates) of any such
patents. ONCOTHYREON PATENT RIGHTS also includes all rights in the FIELD owned by
ONCOTHYREON or licensed in by ONCOTHYREON with the right to sublicense in the manner
contemplated by this AGREEMENT in any foreign patents which correspond to those
described in the preceding sentence and in any patents that claim ONCOTHYREON
IMPROVEMENTS, JOINT IMPROVEMENTS and/or IMPROVEMENTS. Notwithstanding the foregoing,
ONCOTHYREON PATENT RIGHTS shall not include any subsequently

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

7

	 	 	 	developed or acquired ONCOTHYREON PATENT RIGHTS to the extent covering any active
compound that is separate and clearly distinct from PRODUCT, notwithstanding the
fact that such active compound may be useful as part of a combination therapy with
PRODUCT;

	 	1.1.40	 	“ONCOTHYREON TECHNOLOGY” means all ONCOTHYREON PATENT RIGHTS and/or ONCOTHYREON
KNOW-HOW in the FIELD;
	 
	 	1.1.41	 	“ORIGINAL EFFECTIVE DATE” means May 7, 2001;
	 
	 	1.1.42	 	“PRODRUG” means a chemical precursor of PRODUCT which is to be cleaved in a human
being directly into PRODUCT and/or a metabolic intermediate thereof, but excluding for
greater certainty, antigen processing;
	 
	 	1.1.43	 	“PRODUCT” shall mean BLP25;
	 
	 	1.1.44	 	“RIGHTS” has the meaning attributed to that term in section 2.7.2 of this AGREEMENT;
	 
	 	1.1.45	 	“ROW TERRITORY” shall mean all countries in the world except the NA TERRITORY;
	 
	 	1.1.46	 	“SALE” includes, with respect to PRODUCT, the sale thereof to an END USER, and “SOLD”
and “SELL” have a corresponding meaning;
	 
	 	1.1.47	 	“SALES REPORT” has the meaning attributed to that term in section 7.2 of this
AGREEMENT;
	 
	 	1.1.48	 	“SELECTED DOMAIN NAMES” has the meaning attributed to that term in section 5.12.5 of
this AGREEMENT;
	 
	 	1.1.49	 	“SELECTED TRADEMARK” has the meaning attributed to that term in section 5.12.1 of
this AGREEMENT;
	 
	 	1.1.50	 	“TERRITORY” shall mean, collectively, the NA TERRITORY and the ROW TERRITORY;
	 
	 	1.1.51	 	“THIRD PARTY LICENSES” means, collectively, the ICRT LICENSE, the DANA-FARBER
LICENSE, the U of A LICENSE, the CORIXA LICENSE and any other third party license or
sublicense of any technology included as part of the ONCOTHYREON TECHNOLOGY;
	 
	 	1.1.52	 	“TRADEMARK” means the trademarks and logos initially selected for BLP25 pursuant to
section 5.12 of this AGREEMENT, being the trademarks STIMUVAX, STENVAX, STIMRIS, SIATOPE, THEXOPE and JEXAVE;
	 
	 	1.1.53	 	“TRADEMARK DOMAIN NAMES” has the meaning attributed to that term in section 5.12.5 of
this AGREEMENT;

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

8

	 	1.1.54	 	“TRANSFER NOTICE” has the meaning attributed to that term in section 2.7.2 of this
AGREEMENT;
	 
	 	1.1.55	 	“TRANSFER PERIOD” has the meaning attributed to that term in section 2.7.2 of this
AGREEMENT;
	 
	 	1.1.56	 	“U of A LICENSE” means that certain license dated December 1, 2001 with the
University of Alberta in relation to the Samuels MUC1 liposomal formulation patents,
together with all schedules thereto and any amendments to or restatements of such
license agreement; and
	 
	 	1.1.57	 	“VALID CLAIM” means, with respect to PRODUCT in a particular country in the
TERRITORY, a claim of an issued and unexpired patent included within the ONCOTHYREON
PATENT RIGHTS which has not been held unenforceable, unpatentable or invalid by a
decision of a court or other governmental agency of competent jurisdiction,
unappealable or unappealed within the time allowed for appeal, and which has not been
admitted to be invalid or unenforceable through reissue, disclaimer or otherwise.

ARTICLE 2

LICENSE GRANT

Section 2.1 ONCOTHYREON License Grant

Subject to the terms and conditions of this AGREEMENT and only for the purpose of MERCK fulfilling
its obligations and exercising its rights under this AGREEMENT, ONCOTHYREON hereby grants to MERCK
a license (or in the case of ONCOTHYREON TECHNOLOGY that ONCOTHYREON has licensed from a third
party, a sublicense) under the ONCOTHYREON TECHNOLOGY to make, use, import, develop, market and
SELL and have made, used, imported, developed, marketed and SOLD PRODUCT in the FIELD in the NA
TERRITORY and the ROW TERRITORY. Such license shall, except to the extent otherwise provided in
this AGREEMENT or otherwise required by applicable law or regulation (as, for example, in the
European Union under applicable competition law), be exclusive for the FIELD in the NA TERRITORY
and in the ROW TERRITORY, subject to the rights of ONCOTHYREON under this AGREEMENT.

MERCK shall have the right to grant sublicenses (including the right to appoint DISTRIBUTORS of
PRODUCT in the TERRITORY, including AFFILIATES of MERCK) under the licenses obtained under this
AGREEMENT without the prior written consent of ONCOTHYREON provided however, that MERCK, when doing
so, complies with the provisions of the THIRD PARTY LICENSES. MERCK shall be responsible for the
acts and omissions of its DISTRIBUTORS, AFFILIATES, sublicensees and contract manufacturers and
such acts and omissions shall be regarded for purposes of this AGREEMENT as the acts and omissions
of MERCK. ONCOTHYREON agrees not to, and shall cause its wholly owned AFFILIATES not to assert
against MERCK or its sublicensees any patent not included in the ONCOTHYREON PATENT RIGHTS that is
or might be infringed by reason of MERCK or its sublicensees exercise of the licenses granted to
MERCK under this section 2.1. Further, ONCOTHYREON covenants and agrees that for so long as MERCK
has exclusive rights to all

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

9

of the ONCOTHYREON TECHNOLOGY under this AGREEMENT, ONCOTHYREON shall not grant to any third party
rights to the ONCOTHYREON TECHNOLOGY which would permit such third party to make, use, import,
develop, market or SELL or have made, have used, imported, developed, marketed or SOLD PRODUCT for
the treatment of disease in humans.

Section 2.2 Term of Grant

The licenses granted in section 2.1 of this AGREEMENT shall remain in force and effect on a
country-by-country basis until the later of (a) the expiration or termination of the last to expire
or terminate of VALID CLAIMS that cover PRODUCT in such country, and (b) the date which is the
fifteenth (15th) anniversary of the LAUNCH of PRODUCT in any country in the TERRITORY.
Upon the expiration of any such license grant as aforesaid, MERCK shall thereafter, subject to
complying with any applicable provisions of the THIRD PARTY LICENSES (including the payment of any
and all royalties and other amounts required to be paid thereunder), have a paid up, royalty free,
non-exclusive license under the ONCOTHYREON TECHNOLOGY to make, use, import, develop, market and
SELL, and have made, used, imported, developed, marketed and SOLD PRODUCT in such country in the
FIELD.

Section 2.3 Third Party Licenses

With respect to the THIRD PARTY LICENSES to the extent not waived in writing by the licensor under
such THIRD PARTY LICENSES, ONCOTHYREON and MERCK hereby incorporate by reference in this AGREEMENT
any provisions specified in such THIRD PARTY LICENSES to be included in sublicenses of the subject
matter of such THIRD PARTY LICENSES and to make such other amendments to this AGREEMENT as may be
required in connection with the sublicensing of such THIRD PARTY LICENSES by ONCOTHYREON to MERCK.
MERCK also agrees to cooperate with ONCOTHYREON and its AFFILIATES in fully complying in a timely
manner with the terms of such THIRD PARTY LICENSES and, without limiting the generality of the
foregoing, MERCK shall provide to ONCOTHYREON or its designated AFFILIATE in a timely manner or
assist ONCOTHYREON or its designated AFFILIATE in preparing in a timely manner any and all reports,
data, confirmations, approvals and other information that may be required by ONCOTHYREON or its
designated AFFILIATE in connection therewith. ONCOTHYREON shall provide MERCK with examples of
applicable reports previously utilized by ONCOTHYREON and/or its AFFILIATES for such purposes in
order to assist MERCK in preparing the necessary reports.

Section 2.4 Bankruptcy or Insolvency

All rights and licenses granted to MERCK under this article 2 are, and shall be deemed to be, for
purposes of applicable bankruptcy law (including section 365(n) of the United States Bankruptcy
Code), licenses of rights to “intellectual property” (including as such term is defined under
section 101(35A) of the United States Bankruptcy Code). The parties agree that MERCK, as a
licensee of such rights under this AGREEMENT, shall retain and may fully exercise all of its rights
and elections under such applicable bankruptcy law, including but not limited to MERCK’s rights to
continue to exercise all rights licensed hereunder.

Section 2.5 Combination Products

ONCOTHYREON shall not prohibit MERCK from combining for use in the FIELD PRODUCT licensed under
this AGREEMENT with any other product.

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

10

Section 2.6 Covenant Not to Sue or Challenge

MERCK (on behalf of itself and its AFFILIATES and their respective sublicensees) agrees not to in
any way challenge or contest (including by way of an allegation of misuse or non-infringement), nor
assist any other person to challenge or contest, the validity or enforceability of any of the
ONCOTHYREON TECHNOLOGY including, without limitation, the ONCOTHYREON PATENT RIGHTS.

Section 2.7 Exclusivity

	 	2.7.1	 	[+]
	 
	 	2.7.2	 	[+] [Redaction continues for two pages]
	 
	 	2.7.3	 	[+]

ARTICLE 3

REPORTING AND PLANS

Section 3.1 Reporting

On or before March 31, 2009 for the 2009 calendar year, and on or before January 1 for each
subsequent calendar year during the TERM until first commercial SALE of PRODUCT has been made,
MERCK shall provide ONCOTHYREON with a written development plan (the “DEVELOPMENT PLAN”) for
PRODUCT which plan shall outline the CLINICAL DEVELOPMENT activities that MERCK plans to perform in
such calendar year, as well as its manufacturing activities. Upon request of ONCOTHYREON, but no
more than once per calendar quarter, MERCK shall provide ONCOTHYREON with a succinct written update
(i.e. one or two pages) of any material change to the DEVELOPMENT PLAN as well as the progress made
with respect to the CLINICAL DEVELOPMENT, including updates on the status of each ongoing clinical
trial (including the number of patients) and regulatory filings. Upon first commercial SALE of
PRODUCT, the DEVELOPMENT PLAN shall no longer be provided to ONCOTHYREON. In lieu of the
DEVELOPMENT PLAN, MERCK shall provide ONCOTHYREON with a marketing plan (the “MARKETING PLAN”)
which plan shall outline the marketing activities that MERCK plans to perform in the then current
calendar year, as well as its manufacturing activities. Upon request of ONCOTHYREON, but no more
than once per calendar quarter, MERCK shall provide ONCOTHYREON with a succinct written update
(i.e. one or two pages) of any material change to the MARKETING PLAN as well as the progress made
with respect to the marketing of PRODUCT, including updates on the status of each ongoing clinical
trial (including the number of patients) and regulatory filings. Notwithstanding the foregoing,
MERCK shall promptly following any change or event which may be material to ONCOTHYREON in relation
to the subject matter of this AGREEMENT advise ONCOTHYREON together with full particulars thereof.
Such reports and information shall be received by ONCOTHYREON subject to the obligations of Article
8.

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

11

ARTICLE 4

DEVELOPMENT AND MARKET APPROVAL

— NA TERRITORY AND ROW TERRITORY

Section 4.1 CLINICAL DEVELOPMENT Studies and Costs

MERCK will be responsible, and have sole decision making authority, for conducting, or having
conducted, all development (including CLINICAL DEVELOPMENT) and MARKET APPROVAL (including the
preparation, submission and prosecution of all regulatory authority filings and applications
required to obtain all necessary MARKET APPROVALS to SELL PRODUCT in, among others, the NA
TERRITORY and the MAJOR MARKETS in the ROW TERRITORY) tasks necessary and/or desirable for CLINICAL
DEVELOPMENT of PRODUCT in the NA TERRITORY and the ROW TERRITORY. Without limiting the generality
of the foregoing, MERCK agrees to undertake the Phase III clinical trial of BLP25 in Stage III a/b
non-small cell lung cancer described in the protocol set forth in appendix 4. MERCK will bear all
costs in relation to all of the foregoing.

Section 4.2 Regulatory Filings 

MERCK will, at MERCK’s expense, use commercially reasonable efforts to diligently pursue the
preparation, submission and prosecution and maintenance of all regulatory authority filings and
applications required to obtain and maintain all necessary and/or desirable MARKET APPROVALS to
sell PRODUCT in each of the NA TERRITORY, the MAJOR MARKETS in the ROW TERRITORY and in such other
countries in the ROW TERRITORY in which MERCK, using reasonable business judgment, determines to
sell PRODUCT, all in a prudent and skilful manner in accordance with all applicable laws and
regulations. To the extent not already assigned to MERCK, ONCOTHYREON shall promptly assign to
MERCK all applications and filings held by ONCOTHYREON with any regulatory authority relating to
the development, manufacture and commercialization of PRODUCT. MERCK shall keep ONCOTHYREON
informed in respect of the matters which are the subject of this section 4.2 in the manner
specified in Section 3, provided, however, that the final decision on the specifics of the
preparation, submission and prosecution and maintenance of such regulatory filings and applications
shall be made by MERCK. Upon the written request of MERCK, ONCOTHYREON, shall, or shall direct its
AFFILIATE to, either withdraw or transfer to MERCK any drug master file submitted by ONCOTHYREON or
any of its AFFILIATES in relation to the PRODUCT to any regulatory authority in the TERRITORY. For
clarity, any contact to regulatory authorities anywhere in the TERRITORY that relate to the PRODUCT
shall be MERCK’s or its AFFILIATES’ or sublicensees’ responsibility, and any contact made by any
such authority to ONCOTHYREON or any of its AFFILIATES in relation to the PRODUCT shall be referred
promptly by ONCOTHYREON or its AFFILIATE to MERCK.

Section 4.3 MARKET APPROVAL Owner

MERCK shall be the record owner of all MARKET APPROVALS required for SALE of PRODUCT in the NA
TERRITORY and the ROW TERRITORY. Forthwith upon the expiration or termination of this AGREEMENT
with respect to PRODUCT in a particular country in the ROW TERRITORY or the NA TERRITORY, or if any
of the licenses granted by ONCOTHYREON to MERCK in this AGREEMENT become non-exclusive, MERCK shall
in a timely manner comply with section 11.6 of this AGREEMENT in relation to PRODUCT in such
country.

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

12

Section 4.4 Know-How Documentation

In an effort to support the transfer by ONCOTHYREON to MERCK of the ONCOTHYREON KNOW-HOW,
ONCOTHYREON agrees (to the extent legally permitted to do so) to make available to MERCK and its
designated AFFILIATE (with the right to print or photocopy documents at MERCK’s cost) for a period
of two (2) years following the EFFECTIVE DATE, (a) all ONCOTHYREON KNOW-HOW, including (to the
extent falling within the definition of ONCOTHYREON KNOW-HOW) any preclinical data, clinical data,
assays and associated materials, protocols, plans, reports, procedures (including standard
operating procedures), and any other similar information, that is necessary or useful (acting
reasonably) to develop, manufacture, test, release, seek regulatory approval for, or commercialize
BLP25, all to the extent in ONCOTHYREON’s possession or control, (b) copies of all material
communications specifically in relation to BLP25 with regulatory authorities in the possession or
control of ONCOTHYREON, (c) copies of all material communications with third parties related
specifically to the development and manufacture of BLP25 (e.g. communication with contract
manufacturing organizations, vendors, contractors) in the possession or control of ONCOTHYREON, and
(d) copies of all material documents that ONCOTHYREON or its AFFILIATES received from third parties
related specifically to the development and manufacture of BLP25 (e.g. standard operating
procedures, regulatory filing documents, batch records, certificates received from contract
manufacturing organizations, vendors, contractors), in the possession or control of ONCOTHYREON.

ARTICLE 5

PRODUCT MARKETING — NA TERRITORY AND ROW TERRITORY

Section 5.1 Costs and Expenses

MERCK shall bear all costs and expenses associated with the manufacturing, promoting, marketing,
distributing and SALE of PRODUCT in the TERRITORY.

Section 5.2 Sales Force Training

MERCK shall be responsible for developing or having developed (in accordance with all applicable
legal and regulatory requirements) training programs and materials concerning promotion of PRODUCT
in the TERRITORY. MERCK shall also be responsible for developing or having developed (in
accordance with all applicable legal and regulatory requirements) training programs and materials
concerning technical aspects of PRODUCT.

Section 5.3 Costs of Sales Representatives and Specialty Personnel

MERCK shall be responsible for all costs and expenses related to its sales representatives (whether
employees or contracted) in the TERRITORY. MERCK shall be responsible for all costs and expenses
related to “specialty” personnel (including managed care representatives, professional relations,
patient advocacy, reimbursement, specialty sales, and the like) in the TERRITORY.

Section 5.4 Distribution

MERCK shall have the sole responsibility for distribution of PRODUCT in the TERRITORY. In
fulfilling its obligations with respect to the distribution of PRODUCT in the TERRITORY, MERCK
shall use commercially reasonable efforts consistent with accepted pharmaceutical practices. All
costs incurred in relation to such distribution shall be borne by MERCK.

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

13

Section 5.5 Label Content

MERCK shall be responsible for ensuring that the label and product insert for any PRODUCT SOLD in
the TERRITORY shall comply with all legal, governmental and regulatory requirements. Insofar as it
is not contrary to law or regulation in any particular country in the TERRITORY, the box and
package insert, and the label to the extent that space permits, shall include prominent reference
to MERCK (or, if applicable, any AFFILIATE of MERCK designated by MERCK) as marketer and
manufacturer of the PRODUCT and to ONCOTHYREON or its designated AFFILIATE as licensor. Any
trademark or other content as may be from time to time required pursuant to the CORIXA LICENSE
shall be marked on every PRODUCT label and/or insert in the manner required under the CORIXA
LICENSE.

Section 5.6 Product Price

MERCK shall determine the SALES price for PRODUCT SOLD in the TERRITORY.

Section 5.7 Booking Sales

MERCK shall book all SALES of PRODUCT in the TERRITORY.

Section 5.8 Advertising and Promotion

MERCK shall be responsible for determining the sales strategy for SALE of PRODUCT in the TERRITORY,
and shall create, or have created all materials for advertising and promotion of PRODUCT in the
TERRITORY. All costs and expenses incurred in relation to such advertising and promotion shall be
borne by MERCK.

Section 5.9 Customer Complaints and Medical Inquiries

MERCK (or its designated AFFILIATE) shall be responsible for handling all customer complaints and
inquiries regarding PRODUCT in the TERRITORY. All complaints and inquiries received by ONCOTHYREON
or its agents shall be promptly referred to MERCK for response according to applicable law. MERCK
shall use commercially reasonable efforts to handle such matters in a timely, prudent and skilful
manner, in compliance with applicable laws, regulations, rules, policies and regulatory
requirements and in accord with MERCK’s standard operating procedures. MERCK shall keep
ONCOTHYREON informed in a timely manner with respect to MERCK’s activities in regard to customer
complaints and inquiries for PRODUCT. All costs incurred in responding to customer complaints and
inquiries shall be borne by MERCK.

Section 5.10 Adverse Event Reporting

MERCK (or its designated AFFILIATE) shall be responsible for reporting all ADVERSE EVENTS regarding
PRODUCT to the appropriate regulatory authorities in the TERRITORY. All information received by
ONCOTHYREON or its agents shall be promptly transferred according to applicable law to MERCK for
handling. MERCK shall handle such matter in a timely, prudent and skilful manner, in compliance
with all applicable laws, rules, policies, regulations and regulatory requirements, and in accord
with MERCK’s standard operating procedures. MERCK shall keep ONCOTHYREON informed in a timely
manner with respect to MERCK’s activities with respect to ADVERSE EVENT reporting for PRODUCT. All
costs incurred in responding to and reporting ADVERSE EVENTS regarding PRODUCT in the TERRITORY
shall be borne by MERCK.

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

14

Section 5.11 PRODUCT Recall

MERCK (or its designated AFFILIATE) shall be responsible for initiating and implementing all
PRODUCT recalls required by controlling regulatory agencies and for all voluntary PRODUCT market
withdrawals in the TERRITORY. MERCK shall handle such matters in a timely, prudent and skilful
manner, in compliance with all applicable laws, rules, policies, regulations and regulatory
requirements, and in accord with MERCK’s standard operating procedures. MERCK shall keep
ONCOTHYREON informed in a timely manner with respect to MERCK’s activities in regard to recalls and
market withdrawals. All costs incurred in responding to recalls and market withdrawals shall be
borne by MERCK.

Section 5.12 Trademarks and Branding

	 	5.12.1	 	Ownership and Filing. PRODUCT shall be marketed and sold in the TERRITORY
under the applicable trademark selected by MERCK (the “SELECTED TRADEMARK”) which
SELECTED TRADEMARK can be a TRADEMARK or any other trademark selected by MERCK.
ONCOTHYREON acknowledges that MERCK shall be the owner of the TRADEMARKS in the
TERRITORY. ONCOTHYREON shall not knowingly do or cause to be done any act or thing
contesting, challenging or, in any way, impairing or intending to impair any part of
MERCK’s right, title or interest in the TRADEMARKS for the duration of this AGREEMENT.
Further, ONCOTHYREON shall not use or register in the TERRITORY any trademark which is
similar or identical to any of the TRADEMARKS on similar or identical goods or services
to those which are the subject of this AGREEMENT for the duration of this AGREEMENT.
MERCK shall diligently pursue the filing, maintenance and defence of the TRADEMARKS and
the SELECTED TRADEMARKS in the TERRITORY. All trademark-related costs (including,
without limitation, legal, third party, branding, filing, maintenance and other such
costs) of developing, prosecuting, registering, maintaining and defending the
TRADEMARKS and the SELECTED TRADEMARKS shall be borne by MERCK as of March 1, 2006.
	 
	 	5.12.2	 	Trademark License. MERCK hereby grants, in the event that ONCOTHYREON or an
AFFILIATE of ONCOTHYREON obtains the right to manufacture and/or SELL PRODUCT under
this AGREEMENT, to ONCOTHYREON and its designated AFFILIATES a royalty free,
non-exclusive license to use, display, reproduce and publish the TRADEMARKS and/or the
SELECTED TRADEMARKS in connection with the manufacture, use, marketing, promotion,
distribution and SALE of PRODUCT in any countries in the TERRITORY where ONCOTHYREON or
an AFFILIATE of ONCOTHYREON has the right to manufacture and/or SELL PRODUCT under this
AGREEMENT for so long as such right to manufacture and/or SELL exists under this
AGREEMENT. In addition to the foregoing, ONCOTHYREON shall have the right to use the
TRADEMARKS and/or the SELECTED TRADEMARKS in connection with corporate disclosure and
corporate information dissemination. ONCOTHYREON and its designated AFFILIATES shall
have no right to grant sublicenses under such license without the prior written consent
of MERCK (such consent not to be unreasonably withheld). Any goodwill arising from the
use of the TRADEMARKS and/or the SELECTED TRADEMARKS by ONCOTHYREON

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

15

	 	 	 	or its designated AFFILIATES shall inure to the benefit of MERCK. Further, such use
shall be in accordance with the applicable laws in the relevant jurisdiction, as
well as with any reasonable requirements of any brand guide that may be provided by
MERCK from time to time. When using any of the TRADEMARKS and/or the SELECTED
TRADEMARKS under license, ONCOTHYREON and its designated AFFILIATES shall use the
identifiers Ô or â, as appropriate.
	 
	 	5.12.3	 	Assignment. MERCK shall, at MERCK’s cost, arrange for assignment of the
trademarks STENVAX, STIMRIS, SIATOPE, THEXOPE and JEXAVE from ONCOTHYREON or its AFFILIATES to MERCK. Until such assignment is
completed, ONCOTHYREON shall, at MERCK’s cost, provide reasonable cooperation and
assistance with respect to such assignment, including but not limited to providing
documents in ONCOTHYREON’s possession (including its AFFILIATES and external law firm)
and signatures as requested by the relevant trademark offices. A list of currently
identified trademark registrations and applications for STENVAX, STIMRIS, SIATOPE, THEXOPE and JEXAVE are included in appendix 5.
MERCK confirms that ONCOTHYREON and its AFFILIATES are released from all other
obligations under the STIMUVAX letter agreement dated December 21, 2004 including,
without limitation, the 40,000 Euro payment.
	 
	 	5.12.4	 	Trademark Infringement. For countries in which the TRADEMARKS and/or
SELECTED TRADEMARKS are used under license by ONCOTHYREON and/or its AFFILIATES,
ONCOTHYREON shall:

	 	5.12.4.1	 	promptly report to MERCK particulars of any use by any other party of a
trademark, trade name or mode of advertising which comes to ONCOTHYREON’s or
its designated AFFILIATES’ attention and which might qualify as an infringement
of the TRADEMARKS and/or SELECTED TRADEMARKS or as unfair competition; and
	 
	 	5.12.4.2	 	in the event that it comes to the attention of ONCOTHYREON or its
designated AFFILIATES that any party alleges that the TRADEMARKS and/or
SELECTED TRADEMARKS are invalid or that they infringe any rights of a third
party, or that the TRADEMARKS are open to any other form of attack, ONCOTHYREON
or its designated AFFILIATES shall promptly report the matter to MERCK.

In any event described in this section ONCOTHYREON shall not take any action, either
amicably or legally, and shall let MERCK or a nominee of MERCK take any action which
MERCK, acting reasonably, deems necessary, provided, however, that nothing herein
shall prevent ONCOTHYREON from defending and/or protecting its own reasonable
interests. ONCOTHYREON or its designated AFFILIATES, upon MERCK’s reasonable
request and at MERCK’s expense, shall cooperate in any action so taken to the extent
that such cooperation is not materially adverse in interest to ONCOTHYREON and/or
its AFFILIATES.

 
 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

16

	 	5.12.5	 	Domain Names. Any domain names related to the TRADEMARKS (the “TRADEMARK
DOMAIN NAMES”) and/or the SELECTED TRADEMARKS (the “SELECTED DOMAIN NAMES”) in the
TERRITORY shall be selected by MERCK. ONCOTHYREON acknowledges that MERCK shall be the
owner of the TRADEMARK DOMAIN NAMES in the TERRITORY. ONCOTHYREON shall not knowingly
do or cause to be done any act or thing contesting, challenging or, in any way,
impairing or intending to impair any part of MERCK’s right, title or interest in the
TRADEMARK DOMAIN NAMES in the TERRITORY for the duration of this AGREEMENT. Further,
ONCOTHYREON shall not use or register in the TERRITORY any domain name which is similar
or identical to any of the domain names related to the TRADEMARKS on similar or
identical goods or services which are the subject of this AGREEMENT for the duration of
this AGREEMENT. MERCK shall be responsible for the filing, maintenance and defence of
the TRADEMARK DOMAIN NAMES and the SELECTED DOMAIN NAMES in the TERRITORY. All domain
name-related costs (including, without limitation, legal, third party, filing,
maintenance and other such costs) of prosecuting, registering, maintaining and
defending the TRADEMARK DOMAIN NAMES and the SELECTED DOMAIN NAMES or any alternate or
additional domain names shall be borne by MERCK.

	 	5.12.6	 	Domain License. MERCK hereby grants to ONCOTHYREON and its designated
AFFILIATES a royalty free, non-exclusive license to use, display, reproduce and publish
the TRADEMARK DOMAIN NAMES, the SELECTED DOMAIN NAMES or any alternate or additional
domain names under the same terms and under the same circumstances as set forth in
Section 5.12.2.

Section 5.13 General Diligence

Subject to section 14.1 and without being limited by section 5.14, MERCK shall, at MERCK’s expense,
use commercially reasonable efforts to diligently pursue the development (including CLINICAL
DEVELOPMENT), commercialization, manufacture (including commercial scale-up), registration,
promotion, marketing and SALE of PRODUCT in a prudent and skilful manner in accordance with the
DEVELOPMENT PLAN and/or the MARKETING PLAN then in effect, which plans will contain development,
manufacturing and marketing activities representing commercially reasonable efforts, and in
accordance with all applicable laws and regulations. MERCK will bear all costs with respect
thereto.

Section 5.14 Excused Performance

In addition to the terms of section 14.1, MERCK’s performance under this AGREEMENT with respect to
PRODUCT in a particular country is expressly conditioned upon the continuing absence of any safety
or efficacy or regulatory event with respect to PRODUCT in such country which materially limits,
reverses or restricts the development and/or marketing of such PRODUCT in such country. MERCK’s
obligations to develop, promote and/or SELL such PRODUCT in such country under this AGREEMENT shall
be delayed or suspended so long as any such condition exists.

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

17

Section 5.15 Japanese Market

Without derogating from section 5.13, in relation to Japan, MERCK shall, as soon as reasonable
considering the Japanese market and in any event no later than [+] after positive clinical endpoint
data (with no material toxicology issue) being available from a pivotal Phase II or Phase III trial
with respect to PRODUCT, commence discussions with the applicable Japanese regulatory authorities
with respect to initiating any required clinical trials in Japan and finalize a comprehensive
CLINICAL DEVELOPMENT plan for Japan for PRODUCT (which shall include a reasonable timeframe for
obtaining regulatory approval in Japan) and thereafter use commercially reasonable efforts to
pursue such CLINICAL DEVELOPMENT plan within the timeframes stipulated therein. Notwithstanding
any provision to the contrary in this AGREEMENT, if MERCK fails to meet the requirements of this
section 5.15 with respect to Japan, then this AGREEMENT shall cease to apply to PRODUCT in relation
to Japan and all rights related to PRODUCT in Japan shall revert to ONCOTHYREON.

ARTICLE 6

CONSIDERATION — NA TERRITORY AND ROW TERRITORY

Section 6.1 Consideration for Licenses Granted

In consideration for the licenses granted by ONCOTHYREON to MERCK under article 2, MERCK shall, in
the event that MERCK sublicenses, assigns, transfers or otherwise relinquishes all or any of its
rights and/or obligations under this AGREEMENT relating to the NA TERRITORY or any part thereof to
a third party (which term for purposes of this section 6.1 shall not include an AFFILIATE of MERCK
as long as all such rights and/or obligations remain with such AFFILIATE of MERCK, or a contract
manufacturing organization for the development, testing, release or supply of PRODUCT selected by
MERCK) and receives upfront payments, milestone payments, royalty payments or other monetary
consideration, or in-kind consideration of substantive value, in respect thereof, pay ONCOTHYREON
[+] within thirty (30) days of the effective date of such sublicense, assignment, transfer or
relinquishment, provided that no such payment will be due in connection with the transfer or sale
by MERCK of all or substantially all of its business or in the event of the merger or consolidation
of MERCK with another corporation.

Section 6.2 Consideration — Milestone and Other Payments

	 	6.2.1	 	Upfront and Manufacturing Process Transfer Milestone Payments. In
consideration for the licenses granted by ONCOTHYREON to MERCK under Article 2 and
other benefits afforded MERCK under this AGREEMENT, and in addition to the payment
provided for in section 6.1 of this AGREEMENT, the pre LAUNCH milestone payments
provided for in section 6.2.2 of this AGREEMENT, the post LAUNCH milestone payments
provided for in section 6.2.3 of this AGREEMENT and the royalty payments provided for
in section 6.3 of this AGREEMENT, MERCK shall make the payments specified in this
section 6.2.1 to ONCOTHYREON:

	 	6.2.1.1	 	Ten Million Four Hundred Fifty Two Thousand Four Hundred Two Dollars and
Fifty Eight Cents US ($10,452,402.58 US) on the Effective Date;

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

18

	 	6.2.1.2	 	the remaining manufacturing process transfer milestone payment of [+] within
thirty (30) days of the first manufacturing run of PRODUCT (by MERCK or any
AFFILIATE or sub-supplier of MERCK) after upscale of the current process to the
commercial process, provided that, notwithstanding whether or not the
manufacturing process transfer milestone specified in this section 6.2.1.2 has
been met (at all or in part), such milestone payment (to the extent not
previously paid by MERCK to ONCOTHYREON) shall be due and payable by MERCK to
ONCOTHYREON on December 31, 2009;

	 	6.2.1.3	 	MERCK shall be responsible for payment of and shall pay in a timely manner
all royalties and other amounts payable pursuant to the CORIXA LICENSE to the
extent agreed to by CORIXA, and if no such agreement is obtained, reimburse
ONCOTHYREON (or its designated AFFILIATE) for any such payments to CORIXA; and

	 	6.2.1.4	 	for clarification, each of the payments of MERCK identified in this section
6.2.1 is non-refundable to MERCK, and each of the payments identified in
Sections 6.2.1.1 and 6.2.1.2 shall be made only once.

	 	6.2.2	 	Pre LAUNCH Milestone Payments. In consideration for the licenses
granted by ONCOTHYREON to MERCK under Article 2 and other benefits afforded MERCK under
this AGREEMENT, and in addition to the payment provided for in section 6.1 of this
AGREEMENT, the upfront and other payments provided for in section 6.2.1 of this
AGREEMENT, the post LAUNCH milestone payments provided for in section 6.2.3 of this
AGREEMENT and the royalty payments provided for in section 6.3 of this AGREEMENT, MERCK
shall make the following payments to ONCOTHYREON:

	 	6.2.2.1	 	with respect to BLP25 for the first INDICATION:

	 	6.2.2.1.1	 	MERCK shall within thirty (30) days of the date of submission
of a BLA to the FDA for BLP25 for such first INDICATION, pay
ONCOTHYREON [+];
	 
	 	6.2.2.1.2	 	MERCK shall pay ONCOTHYREON [+] within [+] of the date of
submission to the applicable regulatory authority in the first MAJOR
MARKET of a BLA (or its equivalent in the jurisdiction in question)
for BLP25 for such first INDICATION;
	 
	 	6.2.2.1.3	 	MERCK shall pay ONCOTHYREON [+] within thirty (30) days of the
date of receipt of approval of the BLA submitted to the FDA for
BLP25 for such first INDICATION;
	 
	 	6.2.2.1.4	 	MERCK shall pay ONCOTHYREON [+] within thirty (30) days of the
date of receipt of approval of the BLA

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

19

	 	 	 	(or its equivalent in the jurisdiction in question)
submitted to the applicable regulatory authority in the
first MAJOR MARKET for BLP25 for such first INDICATION;

	 	6.2.2.2	 	with respect to BLP25 for the second INDICATION:

	 	6.2.2.2.1	 	MERCK shall within thirty (30) days of the date of submission
of a BLA to the FDA for BLP25 for such second INDICATION pay
ONCOTHYREON [+];
	 
	 	6.2.2.2.2	 	MERCK shall pay ONCOTHYREON [+] within thirty (30) days of the
date of submission to the applicable regulatory authority in the
first MAJOR MARKET of a BLA (or its equivalent in the jurisdiction
in question) for BLP25 for such second INDICATION;
	 
	 	6.2.2.2.3	 	MERCK shall pay ONCOTHYREON [+] within thirty (30) days of the
date of receipt of approval of the BLA submitted to the FDA for
BLP25 for such second INDICATION;
	 
	 	6.2.2.2.4	 	MERCK shall pay ONCOTHYREON [+] within thirty (30) days of the
date of receipt of approval of the BLA (or its equivalent in the
jurisdiction in question) submitted to the applicable regulatory
authority in the first MAJOR MARKET for BLP25 for such second
INDICATION;

	 	6.2.2.3	 	For clarification, each of the milestone payments of MERCK identified in
this section 6.2.2 shall be made only once for the stated milestone triggering
event. Any milestone payments made by MERCK under section 6.2.2 are
non-refundable to MERCK.

	 	6.2.3	 	Post LAUNCH Milestone Payments. In consideration for the licenses
granted by ONCOTHYREON to MERCK under Article 2 and other benefits afforded MERCK under
this AGREEMENT, and in addition to the payment provided for in section 6.1 of this
AGREEMENT, the upfront and other payments provided for in section 6.2.1 of this
AGREEMENT, the pre LAUNCH milestone payments provided for in section 6.2.2 of this
AGREEMENT and the royalty payments provided for in section 6.3 of this AGREEMENT, MERCK
shall pay to ONCOTHYREON the following post-LAUNCH milestone payments within forty-five
(45) days of the end of the applicable period specified below:

	 	6.2.3.1	 	when ROW NET SALES with respect to PRODUCT in any calendar year (following
LAUNCH of PRODUCT anywhere in the TERRITORY) equal or exceed [+], a sales
milestone payment shall be paid by MERCK to ONCOTHYREON of [+];

 
 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

20

	 	6.2.3.2	 	when ROW NET SALES with respect to PRODUCT in any calendar year (following
LAUNCH of PRODUCT anywhere in the TERRITORY) equal or exceed [+], a sales
milestone payment shall be paid by MERCK to ONCOTHYREON of [+];
	 
	 	6.2.3.3	 	when ROW NET SALES with respect to PRODUCT in any calendar year (following
LAUNCH of PRODUCT anywhere in the TERRITORY) equal or exceed [+], a sales
milestone payment shall be paid by MERCK to ONCOTHYREON of [+];
	 
	 	6.2.3.4	 	when ROW NET SALES with respect to PRODUCT in any calendar year (following
LAUNCH of PRODUCT anywhere in the TERRITORY) equal or exceed [+], a sales
milestone payment shall be paid by MERCK to ONCOTHYREON of [+]; and
	 
	 	6.2.3.5	 	when ROW NET SALES with respect to PRODUCT in any calendar year (following
LAUNCH of PRODUCT anywhere in the TERRITORY) equal or exceed [+], a sales
milestone payment shall be paid by MERCK to ONCOTHYREON of [+].

For clarification, each of MERCK’s sales milestone payments identified in this
section 6.2.3 shall be made only once for the stated sales milestone triggering
event. However, more than one sales milestone may be achieved in a particular
calendar year, in which case (if not previously paid) each such sales milestone
payments shall be made by MERCK to ONCOTHYREON. Any sales milestone payments made
by MERCK under this section 6.2.3 are non-refundable to MERCK.

Section 6.3 Royalty Payments

	 	6.3.1	 	In consideration for the licenses granted by ONCOTHYREON to MERCK under
Article 2 and other benefits afforded MERCK under this AGREEMENT, and in addition to
the payment provided for in section 6.1 of this AGREEMENT, the upfront and other
payments provided for in section 6.2.1 of this AGREEMENT, the pre LAUNCH milestones
provided for in section 6.2.2 of this AGREEMENT and the post LAUNCH milestones provided
for in section 6.2.3 of this AGREEMENT, MERCK shall make the payments specified in this
section 6.3 to ONCOTHYREON.
	 
	 	6.3.2	 	With respect to BLP25 in a particular country in the NA TERRITORY, MERCK
shall, until the later of (a) the expiration or termination of the last to expire or
terminate of VALID CLAIMS that cover PRODUCT in such country, and (b) the date which
is the fifteenth (15th) anniversary of the LAUNCH of PRODUCT in any country
in the TERRITORY, pay to ONCOTHYREON on a quarterly basis as specified in article 7 of
this AGREEMENT a royalty on NET SALES of PRODUCT in such country calculated as follows:

	 	6.3.2.1	 	MERCK shall pay ONCOTHYREON a royalty equal to [+] of NET

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

21

	 	 	 	SALES in such country in respect of PRODUCT for such portion of annual
NET SALES in the NA TERRITORY for the calendar year in question up to and
including [+] (pro-rated for stub periods); and
	 
	 	6.3.2.2	 	MERCK shall pay ONCOTHYREON a royalty equal to [+] of NET SALES in such
country in respect of PRODUCT for such portion of annual NET SALES in the NA
TERRITORY for the calendar year in question which exceed [+] (pro-rated for
stub periods).

The royalty rates specified in sections 6.3.2.1 and 6.3.2.2 above shall be reduced
to [+] and [+], respectively, in circumstances where MERCK has paid in full to
ONCOTHYREON in the manner specified in section 6.2.1.2 the remaining manufacturing
process transfer milestone payment in the amount of [+] on or before December 31,
2009.

	 	6.3.3	 	With respect to BLP25 in a particular country in the ROW TERRITORY, MERCK
shall, until the later of (a) the expiration or termination of the last to expire or
terminate of VALID CLAIMS that cover such PRODUCT in such country, and (b) the date
which is the fifteenth (15th) anniversary of the LAUNCH of such PRODUCT in
any country in the TERRITORY, pay to ONCOTHYREON on a quarterly basis as specified in
article 7 of this AGREEMENT a royalty on NET SALES of such PRODUCT in such country
calculated as follows:

	 	6.3.3.1	 	so long as, with respect to the calendar quarter in question, no COMPETITIVE
PRODUCT(S) has actual SALES (based on IMS Global Services data) in such country
which are more than [+] of the actual SALES (based on IMS Global Services data)
of MERCK, its AFFILIATES and their respective permitted sublicensees,
DISTRIBUTORS, assignees and transferees with respect to PRODUCT in such
country, then MERCK shall pay ONCOTHYREON a royalty equal to [+] of NET SALES
in such country in respect of PRODUCT for such calendar quarter (provided that
such [+] royalty rate shall be reduced to [+] in circumstances where MERCK has
paid in full to ONCOTHYREON in the manner specified in section 6.2.1.2 the
remaining manufacturing process transfer milestone payment in the amount of [+]
on or before December 31, 2009);
	 
	 	6.3.3.2	 	if, with respect to the calendar quarter in question, a COMPETITIVE
PRODUCT(S) has actual SALES (based on IMS Global Services data) in such country
which are more than [+] but no more than [+] of the actual SALES (based on IMS
Global Services data) of MERCK, its AFFILIATES and their respective permitted
sublicensees, DISTRIBUTORS, assignees and transferees with respect to PRODUCT
in such country, then MERCK shall pay ONCOTHYREON a royalty equal to [+] of NET
SALES in such country in respect of PRODUCT for such calendar quarter (provided
that such [+] royalty rate shall be

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

22

	 	 	 	reduced to [+] in circumstances where MERCK has paid in full to
ONCOTHYREON in the manner specified in section 6.2.1.2 the remaining
manufacturing process transfer milestone payment in the amount of [+] on
or before December 31, 2009);
	 
	 	6.3.3.3	 	if, with respect to the calendar quarter in question, a COMPETITIVE
PRODUCT(S) has actual SALES (based on IMS Global Services data) which are more
than [+] of the actual SALES (based on IMS Global Services data) of MERCK, its
AFFILIATES and their respective permitted sublicensees, DISTRIBUTORS, assignees
and transferees with respect to PRODUCT in such country, then MERCK shall pay
ONCOTHYREON a royalty equal to [+] of NET SALES in such country in respect of
PRODUCT for such calendar quarter (provided that such [+] royalty rate shall be
reduced to [+] in circumstances where MERCK has paid in full to ONCOTHYREON in
the manner specified in section 6.2.1.2 the remaining manufacturing process
transfer milestone payment in the amount of [+] on or before December 31,
2009).

	 	6.3.4	 	If, with respect to PRODUCT in a particular country in the TERRITORY, MERCK is
able to demonstrate that, for any reason beyond the control of MERCK and its permitted
sublicensees and distributors, the royalty rate payable by MERCK under sections 6.3.2
and 6.3.3 causes or is likely to cause a significant reduction in SALES of PRODUCT in
such country, ONCOTHYREON and MERCK shall meet and in good faith review in such
circumstances the royalty rate applicable to PRODUCT in such country.
	 
	 	6.3.5	 	It is recognized that certain third party rights licensed to ONCOTHYREON under
the THIRD PARTY LICENSES are included in ONCOTHYREON PATENT RIGHTS as indicated in
appendix 3. To the extent such THIRD PARTY LICENSES relate to the TERRITORY,
ONCOTHYREON is solely responsible for all payments due to those third parties, provided
that MERCK acknowledges and agrees that MERCK shall be responsible for the payment of
all royalties and other amounts payable pursuant to the CORIXA LICENSE.
	 
	 	6.3.6	 	No royalties under this section 6.3 shall be payable on PRODUCT used solely by
or on behalf of the parties for tests or development purposes or on transfers between
MERCK and its sublicensees who are not END USERS. Unless ONCOTHYREON and MERCK
otherwise agree in writing, no samples of any PRODUCT shall be made available by MERCK
to END USERS.
	 
	 	6.3.7	 	In establishing the royalty structure of this section 6.3, ONCOTHYREON and
MERCK recognize, and MERCK acknowledges, the substantial value of the various actions
and investments undertaken by ONCOTHYREON prior to the EFFECTIVE DATE. Such value is
significant and in addition to the value of ONCOTHYREON’s grant to MERCK of the license
pursuant to section 2.1 of this AGREEMENT, as it enables the rapid and effective
development and

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

23

	 	 	 	commercialization of PRODUCT in the TERRITORY. Therefore, ONCOTHYREON and MERCK
agree that the royalty payments calculated as a percentage of NET SALES (plus any
other payments provided for elsewhere in this AGREEMENT) provide fair compensation
to ONCOTHYREON for these additional benefits.

ARTICLE 7

ACCOUNTING RECORDS AND PROCEDURES

— NA TERRITORY AND ROW TERRITORY

Section 7.1 Royalty Payments

MERCK shall make royalty payments due ONCOTHYREON under article 6 of this AGREEMENT on a quarterly
basis, within forty-five (45) days following the end of each calendar quarter for which royalties
are due. Each royalty payment shall be accompanied by a SALES REPORT.

Section 7.2 SALES REPORTS

Within forty-five (45) days after the end of each calendar quarter following the first sale of
PRODUCT in the TERRITORY, MERCK shall provide ONCOTHYREON with a detailed report (a “SALES REPORT”)
which will set forth in reasonable detail and with reasonable supporting documentation on a
country-by-country basis (for each country in the TERRITORY):

	 	7.2.1	 	the number of units of PRODUCT sold during such calendar quarter in such
country;
	 
	 	7.2.2	 	the total billings for PRODUCT during such calendar quarter in such country
and in the TERRITORY;
	 
	 	7.2.3	 	the deductions applicable to the determination of NET SALES with respect to
PRODUCT during such calendar quarter in such country;
	 
	 	7.2.4	 	the NET SALES with respect to PRODUCT during such calendar quarter in such
country;
	 
	 	7.2.5	 	the average sales price of PRODUCT during such calendar quarter in such
country;
	 
	 	7.2.6	 	the total royalties due and the basis of the calculation thereof; and
	 
	 	7.2.7	 	such other information as ONCOTHYREON may reasonably request.

Section 7.3 Records and Audits

MERCK will keep and maintain (and, to the extent applicable, will cause its AFFILIATES and their
respective sublicensees, distributors, assignees and transferees to keep and maintain) proper and
complete records and books of account in such form and detail as is necessary for the determination
of the amounts payable by MERCK (on behalf of itself and its AFFILIATES and their respective
sublicensees, distributors, assignees and transferees) to ONCOTHYREON under this AGREEMENT. MERCK
shall at least once in each calendar year during normal business

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

24

hours upon thirty (30) days prior written notice from ONCOTHYREON make those records (and, to the
extent applicable, those of its AFFILIATES and their respective sublicensees, distributors,
assignees and transferees) available for audit by an internationally recognized accounting firm
designated by ONCOTHYREON (except one to which MERCK shall have objection, acting reasonably and
provided such accounting firm agrees to enter into a confidentiality agreement with the audited
party which provides protection for confidential information which is similar to that provided
under article 8 of this AGREEMENT) for the sole purpose of, and MERCK will only be required to
disclose information related to, verifying such payments, revenues, NET SALES, costs, expenses and
deductions and the correctness of calculations and classifications in respect thereof. MERCK shall
preserve (and, to the extent applicable, will cause its AFFILIATES and their respective
sublicensees, distributors, assignees and transferees to preserve) such records made in any
calendar year for a period of seven (7) years following the close of that calendar year. Results
of any such examination shall be made available to each of ONCOTHYREON and MERCK, but all backup
documentation and data shall be made available only to such accounting firm for use only on the
premises of the audited party. In the event that such audit discloses that the actual royalties or
other amounts payable by MERCK to ONCOTHYREON are greater than the royalties or other amounts paid
by MERCK, then MERCK shall pay to ONCOTHYREON any additional royalties and other amounts based on
the results disclosed by such audit. In the event that such audit discloses that the actual
royalties or other amounts payable by MERCK to ONCOTHYREON are less than the royalties or other
amounts paid by MERCK, then ONCOTHYREON shall reimburse MERCK for any such overpayment based on the
results disclosed by such audit. The cost of such audit shall be borne by ONCOTHYREON unless such
audit discloses that the actual royalties and other amounts payable by MERCK to ONCOTHYREON are
greater by five percent (5%) or more than the royalties and other amounts paid by MERCK, in which
case MERCK shall be responsible for payment of all reasonable costs of such audit.

Section 7.4 Payments from Germany

Unless otherwise agreed to in writing by ONCOTHYREON and MERCK, MERCK will make all payments and
reimbursements to ONCOTHYREON under this AGREEMENT from Germany.

Section 7.5 Confidentiality of Financial Reports

Except as otherwise required for purposes of or permitted under this AGREEMENT and except to the
extent disclosure by ONCOTHYREON is required by law or any applicable regulatory authority,
ONCOTHYREON agrees to hold in confidence according to article 8 all information concerning royalty
payments and financial reports, and all information learned in the course of any audit. If
ONCOTHYREON believes, acting reasonably, disclosure is required by law or any applicable regulatory
authority, ONCOTHYREON shall immediately so notify MERCK and shall provide reasonable assistance to
MERCK in maintaining MERCK’s rights at MERCK’s expense.

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

25

ARTICLE 8

CONFIDENTIALITY

Section 8.1 Definition

CONFIDENTIAL INFORMATION is any and all information of a confidential nature including without
limitation DEVELOPMENT PLANS, COMMERCIAL MANUFACTURING PLANS, MARKETING PLANS, any data and/or
information generated under this AGREEMENT, any and all data and/or other information of a
confidential nature which is proprietary to the disclosing party and not generally known (including
without limitation relating to the ONCOTHYREON TECHNOLOGY), and technological information not
limited to compound(s), composition(s), formulation(s) and/or, manufacturing information, and
including business information not limited to commercial forecasts, sales, plans, programs,
customers, assets, financial projections, and costs.

Section 8.2 Obligations

Each party agrees to hold all of the other party’s CONFIDENTIAL INFORMATION received or generated
in connection with this AGREEMENT (either prior to, on, or after the EFFECTIVE DATE) in confidence
and neither disclose it to any third party nor allow any third party access to it nor use it for
any purpose other than as specified by this AGREEMENT. Disclosure by a receiving party of
CONFIDENTIAL INFORMATION of the other party shall only be made to such of its directors, officers,
employees, agents and consultants whose duties require such disclosure and then only if the persons
to whom such CONFIDENTIAL INFORMATION is disclosed are bound by appropriate confidentiality
undertakings. The above notwithstanding, each of MERCK and ONCOTHYREON may disclose CONFIDENTIAL
INFORMATION of the other party to their respective AFFILIATES or distributors on a “need-to-know”
basis provided such persons are bound by like terms of confidentiality as those stated herein.

Section 8.3 Exceptions

These obligations of non-disclosure and non-use shall not apply to CONFIDENTIAL INFORMATION which:

	 	8.3.1	 	was, at the time of disclosure, in the possession of the receiving party (as
evidenced by its written records) and was not previously acquired from or on behalf of
the disclosing party on a confidential basis,
	 
	 	8.3.2	 	was in the public domain prior to disclosure, or became, after disclosure,
publicly known through no fault of the receiving party or any person to whom the
receiving party directly or indirectly provided such CONFIDENTIAL INFORMATION,
	 
	 	8.3.3	 	was received from a third party who rightfully made such disclosure,
	 
	 	8.3.4	 	was approved for use or release by written authorization from the disclosing
party prior to such use or release by the receiving party,
	 
	 	8.3.5	 	is required to be disclosed by operation of law, governmental regulation or
court order provided the receiving party gives the disclosing party written notice of
such required disclosure prior to making such disclosure, and the receiving party

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

26

	 	 	 	uses all reasonable effort to cooperate in securing confidential protection for such
information; or
	 
	 	8.3.6	 	is required to be disclosed to any governmental authority or regulatory
authority to the extent that such disclosure is reasonably necessary to obtain
authorizations to conduct a clinical trial with and to market commercially PRODUCTS,
provided the disclosing party is otherwise entitled to engage in such activities under
this AGREEMENT.

Any specific CONFIDENTIAL INFORMATION shall not be deemed to fall within 8.3.1, 8.3.2, 8.3.3,
8.3.4, 8.3.5 or 8.3.6 above merely because it falls within the scope of more general information
within one of these exceptions.

Section 8.4 Term of Confidentiality

These obligations of confidentiality and non-use are binding throughout the duration of this
AGREEMENT and shall remain in force for a period of ten (10) years from the date of the expiration
or termination of this AGREEMENT.

Section 8.5 Return of Information

Upon termination and upon request from the disclosing party, the receiving party agrees to promptly
return all originals and copies of CONFIDENTIAL INFORMATION received, as well as permanently delete
all electronically or otherwise stored CONFIDENTIAL INFORMATION from all systems containing such
CONFIDENTIAL INFORMATION, except as otherwise required by applicable law and/or regulation and
except that one copy may be retained by legal counsel solely as a measure of the receiving party’s
obligations under this AGREEMENT.

Section 8.6 Publicity

	 	8.6.1	 	Confidentiality. Neither party may disclose any non-public
information regarding the nature and/or occurrence of this transaction, or the nature
and/or occurrence of any event or information occurring as a result of this transaction
without the prior written consent of the other party (such consent not to be
unreasonably withheld), except that each of MERCK and ONCOTHYREON may disclose such
information to their respective AFFILIATES that are under like terms of confidentiality
as those stated herein without such consent and any such information that is required
by law or any applicable regulatory authority to be disclosed (to the extent required
to be disclosed). Where practicable, prior to any required submission of the terms of
this transaction to any governmental agency or authority, the disclosing party shall
provide the other party with a copy of such submission including, without limitation,
identification of any portions of this AGREEMENT which the disclosing party intends to
redact or intends to request the governmental agency or authority to redact, so that
the other party may review and comment on any such proposed submission. The disclosing
party shall initially redact financial terms (and such other material terms as are
appropriate in the circumstances) and will use commercially reasonable efforts to
obtain the concurrence of the governmental agency or authority to such redaction of
financial and other material terms.

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

27

	 	8.6.2	 	Press Release. The parties shall agree on a press release to announce
the execution of this Agreement, and on a Question and Answer (“Q&A”) outline for use
in responding to inquiries about this AGREEMENT. With respect to future press releases
or other public statements relating to the subject matter of this AGREEMENT, including,
but not limited to, webcast materials, press kits and Q&A’s, except to the extent
dealing with subject matter already in the public domain or as required by law or any
applicable regulatory authority (and even then to the extent practicable) and except
with respect to information already in the public domain or previously approved by the
other party, ONCOTHYREON and MERCK shall each provide to the other party a copy of any
proposed press release and the other party shall provide any comments with respect
thereto within the same period of time (which shall be specified, but shall not be less
than twenty-four (24) hours) as the party proposing to issue such press release has
permitted for its own internal review. If no comments are received by the issuing
party within the permitted review period, the press release in question shall be deemed
to have been approved by the other party. If comments are received by the issuing
party within the permitted review period, then the issuing party shall seriously and in
good faith consider such comments and, to the extent such comments are not incorporated
in such press release, only the minimum legally or regulatorily required disclosure
shall be made with respect to such matters.
	 
	 	8.6.3	 	Scientific Publications.
	 
	 	 	 	MERCK, and not ONCOTHYREON (except with respect to research which took place on or
before the EFFECTIVE DATE), shall have the right to present at symposia,
professional meetings, and to publish in academic journals or other similar
publications, accounts of its research relating to the ONCOTHYREON TECHNOLOGY, the
PRODUCT, ONCOTHYREON IMPROVEMENTS, MERCK IMPROVEMENTS and JOINT IMPROVEMENTS which
are the subject of this AGREEMENT, provided that MERCK shall have furnished a copy
of the proposed disclosure at least sixty (60) days in advance of the presentation
or publication date to ONCOTHYREON. ONCOTHYREON shall use the sixty (60) day
period to evaluate the disclosure for patentable content and to, if it so
determines, pursue patent protection with respect thereto.

ARTICLE 9

INVENTIONS AND PATENTS

Section 9.1 JOINT IMPROVEMENTS

All IMPROVEMENTS made jointly by employees or others (including, without limitation, AFFILIATES of
MERCK) acting on behalf of ONCOTHYREON and MERCK (the “JOINT IMPROVEMENTS”) shall be jointly owned
by ONCOTHYREON and MERCK (each party shall have an undivided, one-half interest). JOINT
IMPROVEMENTS shall be managed pursuant to section 9.7.

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

28

Section 9.2 ONCOTHYREON IMPROVEMENTS

IMPROVEMENTS made solely by employees or others acting on behalf of ONCOTHYREON (the “ONCOTHYREON
IMPROVEMENTS”) shall be owned solely by ONCOTHYREON, and, in the circumstances specified in the
definition of BLP25, shall be subject to the licenses granted to MERCK in article 2.
Notwithstanding any provision to the contrary in this AGREEMENT, ONCOTHYREON shall have the right,
but not the obligation, to file, prosecute and maintain patent protection for ONCOTHYREON
IMPROVEMENTS to be licensed hereunder and, MERCK shall pay, to the extent Merck was given the
opportunity to select the respective countries in which to protect the same, one hundred percent
(100%) of the filing, prosecution, maintenance and defense costs associated with such patent
applications or patents and the use of the technology represented thereby and one hundred percent
(100%) of the development (including clinical development), scale-up and other costs associated
therewith throughout the TERRITORY. ONCOTHYREON may at any time, upon written notice to MERCK,
elect not to file, or cease prosecuting, defending and/or maintaining any patent and/or patent
application forming part of the ONCOTHYREON IMPROVEMENTS and shall, if requested in writing by
MERCK within forty-five (45) days of the receipt by MERCK of the aforementioned written notice from
ONCOTHYREON, assign such invention, patent and/or patent application, either in total or on a
country-by-country basis, to MERCK and MERCK shall bear one hundred percent (100%) of the
assignment costs in connection therewith and continue to bear one hundred percent (100%) of the
filing, production, maintenance and defence costs.

Section 9.3 MERCK IMPROVEMENTS

IMPROVEMENTS made solely by employees or others (including, without limitation, AFFILIATES of
MERCK) acting on behalf (including, without limitation, pursuant to any general services or other
similar agreement) of MERCK (the “MERCK IMPROVEMENTS”) shall be owned solely by MERCK. MERCK shall
have the right to file, prosecute and maintain at its cost patent protection for MERCK
IMPROVEMENTS.

Section 9.4 Determination of Inventorship

Inventorship shall be determined in accordance with U.S. patent law.

Section 9.5 Invention Disclosure

ONCOTHYREON shall promptly disclose to MERCK and MERCK shall promptly disclose to ONCOTHYREON any
IMPROVEMENTS arising under this AGREEMENT. Each party agrees to hold such disclosure from the
other party on a confidential basis under the same terms regarding confidentiality as described in
article 8. Each party agrees to keep the other party informed of the filing and status of any
patent application or patent pertaining to this AGREEMENT and shall consider any comments or
suggestions from the other party with respect thereto.

Section 9.6 Independent Use of JOINT IMPROVEMENTS

Within the FIELD the use of JOINT IMPROVEMENTS shall only be for purposes of and pursuant to the
terms and conditions of this AGREEMENT. Outside of the FIELD the parties shall each be entitled to
use JOINT IMPROVEMENTS as such party determines, provided that prior to a party licensing any such
JOINT IMPROVEMENT to a third party such party shall consult with the other party with the aim of
jointly licensing such JOINT IMPROVEMENT to

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

29

such third party. In the absence of a joint license, neither party may license a JOINT IMPROVEMENT
to a third party without the prior written consent of the other party.

Section 9.7 Prosecution and Maintenance of Joint Patents

	 	9.7.1	 	Filing, Prosecution and Maintenance. ONCOTHYREON and MERCK shall
determine, with respect to each JOINT IMPROVEMENT, the procedure and responsibility for
filing, prosecuting and maintaining patent applications with respect to such JOINT
IMPROVEMENTS. Unless otherwise agreed in writing, all reasonable costs incurred with
respect to the filing, prosecution and maintenance of patent applications and patents
covering JOINT IMPROVEMENTS, including fees and expenses of patent counsel, shall be
borne equally by the parties. Notwithstanding that one party may be delegated
responsibility for filing, prosecuting and maintaining patent applications with respect
to a particular JOINT IMPROVEMENT, the other party must approve in writing the taking
of any material action with respect thereto including without limitation approving any
patent application prior to filing. Both ONCOTHYREON and MERCK shall have the right to
participate fully in the formation and implementation of patent strategy.
	 
	 	9.7.2	 	Cooperation. Each party shall reasonably make available to the other
party or its authorized attorneys, agents or representatives, its employees, agents or
consultants (including, without limitation, AFFILIATES of MERCK) necessary or
appropriate to enable the appropriate party to file, prosecute and maintain patent
applications and resulting patents with respect to all JOINT IMPROVEMENTS, for a period
of time sufficient for such party to obtain the assistance it needs from such
personnel. All reasonable costs incurred by either party in providing such cooperation
shall be shared equally by the parties.
	 
	 	9.7.3	 	Failure to Agree. In the case of a failure of ONCOTHYREON and MERCK
to agree upon whether or in which countries patent applications should be filed and
prosecuted for JOINT IMPROVEMENTS, the party which desires to proceed may file and
prosecute the patent applications in its own name and at its own expense, and shall
maintain such patents at its own expense. If either ONCOTHYREON or MERCK wishes to
discontinue its portion of payment for maintenance of any patent on the JOINT
IMPROVEMENTS, such party may do so with prior written notice to the other party, and
the other party may maintain such patent on the JOINT IMPROVEMENTS at its own expense.
Notwithstanding the foregoing, either party may reacquire its rights in any patents or
patent applications in any country relating to the JOINT IMPROVEMENTS by paying its
portion of any costs incurred by the other party to such other party.

Section 9.8 No Waiver

By entering into this AGREEMENT, subject to the licenses granted in this AGREEMENT, neither party
waives or forfeits any of its rights to any patent that it owns and that exists at the EFFECTIVE
DATE, or to any IMPROVEMENT that it owns either jointly or solely.

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

30

Section 9.9 Cooperation with Respect to Patents

	 	9.9.1	 	The parties acknowledge and agree that it is in their mutual interest to
cooperate with respect to the filing, prosecution and maintenance of the ONCOTHYREON
PATENT RIGHTS in the FIELD. Therefore, with respect to the ONCOTHYREON PATENT RIGHTS
in the FIELD, ONCOTHYREON agrees to keep MERCK informed on a regular basis of its
patent strategy, proposed new patent applications and the filing and status of any
patent application or patent and to consider in good faith any comments or suggestions
of MERCK with respect thereto, subject to MERCK agreeing to appropriate safeguards with
respect to the ownership of such proprietary rights. MERCK agrees to hold such
disclosure from ONCOTHYREON on a confidential basis under the same terms regarding
confidentiality as described in article 8.
	 
	 	9.9.2	 	Subject to the other provisions of this article 9, ONCOTHYREON covenants and
agrees to use reasonable commercial efforts to prosecute and, prior to the expiration
or termination thereof, defend and maintain the ONCOTHYREON PATENT RIGHTS in the CORE
PATENT COUNTRIES during the term of this AGREEMENT, provided that ONCOTHYREON may at
any time, upon written notice to MERCK, cease prosecuting, defending and/or maintaining
any patent and/or patent application forming part of the ONCOTHYREON PATENT RIGHTS and
shall, if requested in writing by MERCK within forty-five (45) days of the receipt by
MERCK of the aforementioned written notice from ONCOTHYREON, assign such patent and/or
patent application, either in total or on a country-by-country basis, to MERCK. In the
event that MERCK requests to take over any such patent or patent application as
aforesaid, MERCK shall be responsible for all costs and expenses incurred in connection
with transferring such rights to MERCK and all ongoing costs and expenses in connection
with the prosecution, defence and maintenance of such rights (including without
limitation any liability and/or amounts payable with respect thereto pursuant to
section 10.2). Notwithstanding the foregoing but always subject to the other
provisions of this article 9, MERCK shall have the right in circumstances where MERCK
has assumed such obligations as aforesaid, at MERCK’S election, to (i) charge to
ONCOTHYREON all reasonable costs and expenses incurred by MERCK or its designated
AFFILIATE in connection with the prosecution, defence and maintenance of such patent or
patent application in such CORE PATENT COUNTRY notwithstanding the assignment thereof
to MERCK, or (ii) deduct such reasonable costs and expenses incurred by MERCK or its
designated AFFILIATE in connection with the prosecution, defence and maintenance of
such patent or patent application in such CORE PATENT COUNTRY from any payment
obligations that MERCK has vis-à-vis ONCOTHYREON or its AFFILIATES under this
AGREEMENT.

Section 9.10 Merck Manufacturing Activities

Notwithstanding any other provision to the contrary in this AGREEMENT, ONCOTHYREON and MERCK agree
that any manufacturing activities pursued or undertaken by or on behalf of MERCK or any of its
AFFILIATES or their respective sublicensees, contract manufacturers, and the like, after the
EFFECTIVE DATE (the “MERCK MANUFACTURING ACTIVITIES”)

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

31

which are at variance with or different from those undertaken by ONCOTHYREON prior to the EFFECTIVE
DATE shall be the sole responsibility, and at the risk, of MERCK.

ARTICLE 10

PATENT INFRINGEMENT

Section 10.1 Infringement by Third Parties

	 	10.1.1	 	Notification. If any claims in ONCOTHYREON PATENT RIGHTS licensed to MERCK
hereunder or in patent rights covering a JOINT IMPROVEMENT (“JOINT IMPROVEMENT PATENT
RIGHTS”) are believed to be infringed by a third party in a country where PRODUCT is
being or will be sold, the party first having knowledge of such infringement shall
promptly so notify the other party in writing. Such notice shall set forth in
reasonable detail the facts of that infringement as are then known.
	 
	 	10.1.2	 	Initiating Proceedings. ONCOTHYREON shall have the primary right, but not
the obligation, to initiate, prosecute, and control any action or proceeding with
respect to such infringement. If ONCOTHYREON fails to initiate proceedings intended to
remedy such infringement within ninety (90) days of receiving written notice of such
infringement, then MERCK may bring and control any such action. If one party initiates
proceedings intended to remedy such infringement, then the other party shall be kept
fully informed with respect to such proceedings and shall be consulted in relation to
all material discussions concerning such proceedings. Further, the other party agrees
to cooperate and give reasonable assistance, including agreeing to be joined as a party
plaintiff if suit is filed. The party which brings and controls proceedings against an
alleged infringer will do so at its own expense. If the other party chooses to be
represented by counsel of its own choice in any such proceeding, then that party may be
so represented, but at its own expense.
	 
	 	10.1.3	 	Distribution of Awards. Any monetary award received as a result of
proceedings contemplated by this section 10.1 shall first be used to compensate
ONCOTHYREON and MERCK for their respective reasonable expenses incurred in connection
with such proceedings (provided that if the monetary award is not sufficient to
compensate both ONCOTHYREON and MERCK for their reasonable expenses incurred in
connection with such proceedings, then such monetary award shall be apportioned pro
rata based on the reasonable expenses of each of the parties). Any award monies
remaining after such reimbursement shall (to the extent such award monies represent
compensation for lost SALES of PRODUCT) be added to NET SALES for the calendar quarter
in which they are received and then dealt with in the manner prescribed in this
AGREEMENT for such NET SALES. Any remaining award monies which do not represent
compensation for lost sales of PRODUCT shall be shared equally by the parties.
	 
	 	10.1.4	 	Voluntary Disposition. No settlement or consent judgment or other voluntary
final disposition of a suit under this section 10.1 may be entered into by either

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

32

party without the prior consent of the other party, such consent not to be
unreasonably withheld.

Section 10.2 Claims Against ONCOTHYREON TECHNOLOGY and JOINT TECHNOLOGY

	 	10.2.1	 	Notice.

	 	10.2.1.1	 	If a third party asserts that a patent or other right owned by it is
infringed by ONCOTHYREON’s and/or MERCK’s use or sale in the manner prescribed
in this AGREEMENT of any ONCOTHYREON PATENT RIGHTS, the party first obtaining
knowledge of such claim shall immediately provide the other party with written
notice of such claim and the related facts as are then known, in reasonable
detail. ONCOTHYREON shall have the primary right, but not the obligation to,
control the defense and settlement of any such claim at its expense. If
ONCOTHYREON fails to assume the control and settlement of any such claim within
ninety (90) days of receiving written notice thereof, then MERCK may control
the defense and settlement of such action. The controlling party shall keep
the non-controlling party fully informed with respect to all matters in
relation to such claim and shall consult with the non-consulting party in
relation to all material discussions concerning such claim and the defense
thereof. The non-controlling party agrees to cooperate and provide reasonable
assistance in defending such claims. No settlement shall be entered into
without the prior written consent of ONCOTHYREON and MERCK, such consent not to
be unreasonably withheld.
	 
	 	10.2.1.2	 	If a third party asserts that a patent or other right owned by it is
infringed by the use, in the manner prescribed in this AGREEMENT, of any JOINT
IMPROVEMENTS, the party first obtaining knowledge of such claim shall
immediately provide the other party with written notice of such claim and the
related facts as are then known, in reasonable detail. Both parties shall
share in the control of the defense and settlement of any such claim. Each
party shall keep the other party fully informed with respect to all matters in
relation to such claim and shall consult with the other party in relation to
all material discussions concerning such claim and the defense thereof. The
parties agree to cooperate and provide reasonable assistance to the other in
defending such claims. No settlement shall be entered into without the prior
written consent of ONCOTHYREON and MERCK, such consent not to be unreasonably
withheld.

	 	10.2.2	 	Damages.

	 	10.2.2.1	 	Subject to section 10.2.3, after complying fully with the procedures set
forth in section 10.2.1.1, any damages or other payments that result from a
claim of infringement as specified in section 10.2.1.1 that are

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

33

	 	 	 	required to be paid as a result of reaching a settlement with a third
party in the manner prescribed in section 10.2.1.1 or as a result of a
judgment from a competent court (which is unappealable or with respect to
which the appeal period has expired), shall be:

	 	10.2.2.1.1	 	shared equally by ONCOTHYREON and MERCK to the extent such
infringement relates to the NA TERRITORY or to the ROW TERRITORY
with respect to JOINT IMPROVEMENTS;
	 
	 	10.2.2.1.2	 	paid by ONCOTHYREON to the extent such infringement relates
to the NA TERRITORY or the ROW TERRITORY with respect to
ONCOTHYREON PATENT RIGHTS other than IMPROVEMENTS, JOINT
IMPROVEMENTS or as a result of MERCK MANUFACTURING ACTIVITIES; and
	 
	 	10.2.2.1.3	 	paid by MERCK to the extent such infringement relates to
IMPROVEMENTS, MERCK MANUFACTURING ACTIVITIES or to the extent
contemplated in section 10.2.4.

	 	 	 	Finally, the reasonable costs and expenses of the parties in defending
and settling any such action shall be borne by the responsible
party(ies) as set forth above.
	 
	 	10.2.2.2	 	After complying fully with the procedures set forth in section 10.2.1.2,
any damages or other payments that result from a claim of infringement as
specified in section 10.2.1.2 that are required to be paid as a result of
reaching a settlement with a third party in the manner prescribed in section
10.2.1.2 or as a result of a judgment from a competent court (which is
unappealable or with respect to which the appeal period has expired), shall be
shared equally by ONCOTHYREON and MERCK. Finally, the reasonable costs and
expenses of the parties in defending and settling any such action shall be
shared equally by ONCOTHYREON and MERCK.

	 	10.2.3	 	Royalty Payable to Third Party.
	 
	 	 	 	In the event that MERCK, after permitting ONCOTHYREON to defend against any such
allegation of infringement in the manner provided for in this article 10, is
obligated to pay a royalty to a third party (for which ONCOTHYREON is liable
pursuant to section 10.2.2.1) because the use and sale in the manner specified in
this AGREEMENT of PRODUCT in a country in the ROW TERRITORY or the NA TERRITORY
infringes one or more patents held by a third party claiming subject matter that is
also claimed in the ONCOTHYREON PATENT RIGHTS (but excluding ONCOTHYREON
IMPROVEMENTS, MERCK

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

34

	 	 	 	IMPROVEMENTS, JOINT IMPROVEMENTS and MERCK MANUFACTURING ACTIVITIES), then MERCK may
reduce the royalties otherwise payable to ONCOTHYREON under section 6.3 of this
AGREEMENT for PRODUCT in the applicable country by fifty percent (50%) of the amount
of all such royalties, license fee and other license payments properly paid by MERCK
to such third party, provided that in no circumstances shall the royalties otherwise
payable under this AGREEMENT by MERCK to ONCOTHYREON for PRODUCT in such country be
reduced to less than sixty percent (60%) of the amount otherwise payable.
	 
	 	10.2.4	 	Subject to Section 9.9.2.
	 
	 	 	 	The provisions of this section 10.2 do not apply to any ONCOTHYREON PATENT RIGHTS
taken over by MERCK under section 9.9.2 to the extent that MERCK’s (or those of its
AFFILIATES and their respective sublicensees, DISTRIBUTORS, contract manufacturers,
assignees and/or transferees) acts or omissions have contributed to the infringement
in question or claim thereof, and in all such cases and to the extent that MERCK’s
(or those of its AFFILIATES and their respective sublicensees, DISTRIBUTORS,
contract manufacturers, assignees and/or transferees) acts or omissions have
contributed to the infringement in question or claim thereof, MERCK shall be solely
responsible for all payments, costs and expenses in connection therewith.

ARTICLE 11

TERM AND TERMINATION

Section 11.1 Term and Expiration

This AGREEMENT shall be effective as of the EFFECTIVE DATE and, unless terminated earlier pursuant
to this article 11, this AGREEMENT shall remain in force and effect on a country-by-country basis
until the later of (a) the expiration or termination of the last to expire or terminate of VALID
CLAIMS that cover PRODUCT in such country, and (b) the date which is the fifteenth
(15th) anniversary of the LAUNCH of PRODUCT in any country in the TERRITORY.

Section 11.2 Early Termination

This AGREEMENT may be terminated as follows:

	 	11.2.1	 	by mutual written agreement of ONCOTHYREON and MERCK, effective as of the time
specified in such written agreement; or
	 
	 	11.2.2	 	by either party, upon any breach of this AGREEMENT by the other party of any
obligation to make payments required hereunder, which failure to make payment is not
the subject of a legitimate, good faith dispute between the parties, provided, however,
that the party alleging such breach must first give the other party written notice
thereof, which notice must identify the breach in reasonable detail and that the party
giving such notice views such alleged breach as a basis for terminating this AGREEMENT
under this section 11.2.2 and the party receiving such notice

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

35

	 	 	 	must have failed to cure such alleged breach within forty-five (45) days after
receipt of such notice; or
	 
	 	11.2.3	 	by either party, upon any material breach of this AGREEMENT by the other party,
provided, however, that the party alleging such material breach must first give the
other party written notice thereof, which notice must identify the breach in reasonable
detail and that the party giving such notice views such alleged material breach as a
basis for terminating this AGREEMENT under this section 11.2.3 and the party receiving
such notice must have failed to cure such alleged material breach within ninety (90)
days after receipt of such notice or, such longer period of time as the party alleging
such material breach may agree to in writing as a result of the good faith efforts of
the other party to resolve such material breach in a timely manner; or
	 
	 	11.2.4	 	by either party, in the event that the other party institutes any proceedings under
any statute or otherwise relating to insolvency or bankruptcy, or should any
proceedings under any such statute or otherwise be instituted against such party and
not be dismissed or vacated within ninety (90) days of the date of commencement of such
proceedings;
	 
	 	11.2.5	 	by MERCK upon thirty (30) days prior written notice to ONCOTHYREON if, in the
exercise of MERCK’s reasonable judgment, MERCK determines that there are issues
concerning the safety or efficacy of PRODUCT which materially adversely affects
PRODUCT’s medical, economic or competitive viability, provided that if ONCOTHYREON does
not agree with such determination and notifies MERCK to that effect within ten (10)
days following receipt by ONCOTHYREON of MERCK’s written notice of termination, the
matter shall be submitted to binding arbitration before an expert or expert panel in
the field of clinical drug development, such expert or expert panel to be appointed by
ONCOTHYREON and MERCK in accordance with the procedure under section 14.7 of this
AGREEMENT.

Section 11.3 Continuing Liability

Termination of this AGREEMENT for any reason shall not release any party from any liability,
obligation or agreement which has already accrued nor affect the survival of any provision hereof
which is expressly stated to survive such termination. Termination of this AGREEMENT for any
reason shall not constitute a waiver or release of, or otherwise be deemed to prejudice or
adversely affect, any rights, remedies or claims, whether for damages or otherwise, which a party
may have hereunder or which may arise out of or in connection with such termination.

Section 11.4 Disposition of Inventory

MERCK may dispose of its inventory of PRODUCT on hand as of the effective date of termination, and
may fill any orders for PRODUCT accepted prior to the effective date of termination, for a period
of twelve (12) months after the effective date of termination, and, within thirty (30) days after
disposition of such inventory and fulfilment of such orders (and in any event within fourteen (14)
months after termination) MERCK will forward to

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

36

ONCOTHYREON a final report and pay all royalties or other amounts due for NET SALES in such period.

Section 11.5 Rights and Cooperation on Termination 

Upon the termination of this AGREEMENT in its entirety, or with respect to a particular country,
the parties shall cooperate so as to minimize the impact of such termination on both parties.
ONCOTHYREON and its AFFILIATES shall have the right to use any and all proprietary information and
data relating to the manufacture of PRODUCT and any and all preclinical and clinical trial results
and related data relating to PRODUCT that are developed by or on behalf of ONCOTHYREON and/or MERCK
(including, without limitation, MERCK’s AFFILIATES) after the ORIGINAL EFFECTIVE DATE pursuant to
this AGREEMENT (including without limitation all such results and data used or developed by MERCK
(including, without limitation, MERCK’s AFFILIATES) in support of applications for MARKET
APPROVAL), all MARKET APPROVALS shall be assigned to ONCOTHYREON or its designated AFFILIATE by
MERCK (of its applicable AFFILIATE) as soon as is reasonably practicable, and all third party
manufacturing agreements and related rights used to manufacture PRODUCT shall be assigned to
ONCOTHYREON or its designated AFFILIATE by MERCK (or its applicable AFFILIATE) as soon as is
reasonably practicable. For ONCOTHYREON requested proprietary information and data relating to the
manufacture of PRODUCT only (whether patent protected or not), ONCOTHYREON shall pay to MERCK such
reasonable compensation as is agreed to in writing by ONCOTHYREON and MERCK, acting reasonably, in
good faith and in a timely manner, and, if not agreed to by MERCK and ONCOTHYREON within forty-five
(45) days of the date of termination of this AGREEMENT, such compensation shall be determined
pursuant to section 14.7 of this AGREEMENT. To the extent required in connection with the
foregoing, MERCK hereby grants to ONCOTHYREON and its AFFILIATES an irrevocable, non-exclusive,
royalty-free (subject to the compensation to be paid by ONCOTHYREON to MERCK described above)
license to use such proprietary technology, information and data relating to the manufacture of
PRODUCT and such preclinical and clinical trial results and data in the TERRITORY. Finally, for a
period not to exceed [+] from termination, MERCK shall supply sufficient PRODUCT to ONCOTHYREON or
its designated AFFILIATE to meet such requirements at a cost equal to [+] of the MERCK COST OF
GOODS incurred by or on behalf of MERCK in connection with the manufacture of such PRODUCT and
otherwise reasonably assist ONCOTHYREON and/or its designated AFFILIATE, at ONCOTHYREON’s expense,
to manufacture or have manufactured PRODUCT.

Section 11.6 Rights and Cooperation on Expiration

Upon expiration of this AGREEMENT with respect to a particular country as provided for in section
11.1 of this AGREEMENT, or if any of the licenses granted by ONCOTHYREON to MERCK in this AGREEMENT
with respect to PRODUCT in such country become non-exclusive, MERCK shall (i) permit ONCOTHYREON or
its designated AFFILIATE to utilize all MARKET APPROVALS owned by MERCK and/or its AFFILIATES with
respect to PRODUCT in such country (ii) permit ONCOTHYREON or its designated AFFILIATE to use any
and all proprietary information and data relating to the manufacture of PRODUCT and any and all
preclinical and clinical trial results and related data relating to PRODUCT developed by or on
behalf of MERCK and its AFFILIATES, (iii) supply, for a period of not to exceed [+] from such
expiration, sufficient PRODUCT to ONCOTHYREON or its designated AFFILIATE to meet their
requirements at a cost equal to [+] of the MERCK COST OF GOODS incurred by or

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

37

on behalf of MERCK in connection with the manufacture of such PRODUCT and otherwise reasonably
assist ONCOTHYREON and/or its designated AFFILIATE, at ONCOTHYREON’s expense, to manufacture or
have manufactured PRODUCT, and (iv) take all other actions reasonably necessary to permit
ONCOTHYREON or its designated AFFILIATE to commence the manufacture, marketing and SALE of PRODUCT
in such country. Such actions may include, but shall not be limited to, the filing of duplicate
MARKET APPROVALS upon ONCOTHYREON’s request and at its sole expense, and granting ONCOTHYREON
permission to cross-reference, copy and duplicate the MARKET APPROVALS. For ONCOTHYREON requested
proprietary information and data relating to the manufacture of PRODUCT only (whether patent
protected or not), ONCOTHYREON shall pay to MERCK such reasonable compensation as is agreed to in
writing by ONCOTHYREON and MERCK, acting reasonably, in good faith and in a timely manner, and, if
not agreed to by MERCK and ONCOTHYREON within forty-five (45) days of the date of termination of
this AGREEMENT, such compensation shall be determined pursuant to section 14.7 of this AGREEMENT.
To the extent required in connection with the foregoing, MERCK hereby grants to ONCOTHYREON and its
AFFILIATES an irrevocable, non-exclusive, royalty-free (subject to the compensation to be paid by
ONCOTHYREON to MERCK described above) license to use such proprietary technology, information and
data relating to the manufacture of PRODUCT and such preclinical and clinical trial results and
data in the TERRITORY.

ARTICLE 12

REPRESENTATIONS AND WARRANTIES

Section 12.1 Corporate Existence and Power

Each party represents and warrants to the other party that, as of the EFFECTIVE DATE, (a) it is a
corporation duly organized and validly existing and in good standing, under the laws of the
jurisdiction of its incorporation; (b) it has the corporate power and authority and the legal
right to own its property and assets, to lease the property and assets it operates under lease, and
to carry on its business as it is now being conducted; and (c) it is in compliance with all
requirements of applicable law, except to the extent that any non-compliance would not have a
material adverse effect on the properties, business, financial or other condition of such party and
would not materially adversely affect such party’s ability to perform its obligations under this
AGREEMENT.

Section 12.2 Authorization and Enforcement of Obligations

Each party represents and warrants to the other party that, as of the EFFECTIVE DATE, it has the
corporate power and authority and legal right to enter into this AGREEMENT and to perform its
obligations hereunder; and that this AGREEMENT has been duly executed and delivered on behalf of
each party and, except as it may be limited by applicable law, constitutes a legal, valid, binding
obligation, according to its terms.

Section 12.3 Consents

Subject to section 2.3 of this AGREEMENT, each party represents and warrants to the other party
that, as of the EFFECTIVE DATE, all necessary consents, approvals and authorizations of all
governmental authorities and others required to be obtained by such party in connection with this
AGREEMENT have been obtained.

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

38

Section 12.4 No Conflict

Subject to section 2.3 of this AGREEMENT, each party represents and warrants to the other party
that, as of the EFFECTIVE DATE, the execution and delivery of this AGREEMENT and the performance of
such party’s obligations hereunder do not conflict with or violate any requirement of applicable
laws or regulations, and do not conflict with, or constitute a default under any contractual
obligation of such party.

Section 12.5 Authorization of Obligations

The execution, delivery and performance by each party of this AGREEMENT have been duly authorized
by all necessary corporate action and do not and will not (a) require any consent or approval of
its stockholders or, subject to section 2.3 of this AGREEMENT, any other third party that has not
been received by the EFFECTIVE DATE, (b) violate any provision of any law, rule, regulation, order,
writ, judgment, injunction, decree, determination or award presently in effect that have
applicability to it or any provision of its charter documents or (c) result in a breach of or
constitute a default under any material agreement, mortgage, lease, license, permit or other
instrument or obligation to which it is a party or by which it or its properties may be bound or
affected.

Section 12.6 ONCOTHYREON Representations 

	 	12.6.1	 	ONCOTHYREON represents and warrants to MERCK that as of the EFFECTIVE DATE (but
subject to section 2.3 and the need to obtain the consents of the licensees under the
THIRD PARTY LICENSES):

	 	12.6.1.1	 	to ONCOTHYREON’s knowledge after due inquiry, ONCOTHYREON is the sole owner
of, or the exclusive licensee or sublicensee (on the terms described in the
applicable licensee agreement) in the NA TERRITORY and the ROW TERRITORY of the
ONCOTHYREON PATENT RIGHTS and the ONCOTHYREON KNOW-HOW in existence as at the
EFFECTIVE DATE, with the right to grant to MERCK the rights granted in this
AGREEMENT, free and clear (except to the extent specified in the THIRD PARTY
LICENSES) of any liens or encumbrances which would prevent or impair the grant
of such rights;
	 
	 	12.6.1.2	 	ONCOTHYREON has not assigned or conveyed any interest in the ONCOTHYREON
PATENT RIGHTS or the ONCOTHYREON KNOW-HOW in existence as at the EFFECTIVE DATE
and licensed to MERCK under this AGREEMENT, or entered into any agreement or
made any commitment which is inconsistent with or in derogation of the rights
granted to MERCK hereunder;
	 
	 	12.6.1.3	 	as at the EFFECTIVE DATE, ONCOTHYREON has not received from any third party
any written notice to the effect that the ONCOTHYREON PATENTS or the
ONCOTHYREON KNOW-HOW infringe the proprietary rights of any such third party;

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

39

	 	12.6.1.4	 	there is no action, suit, proceeding, alternative dispute resolution,
mediation or investigation pending or, to the knowledge of ONCOTHYREON,
threatened against ONCOTHYREON relating to the ONCOTHYREON PATENT RIGHTS or the
ONCOTHYREON KNOW-HOW;
	 
	 	12.6.1.5	 	to ONCOTHYREON’s knowledge after due inquiry, no third party rights are
required in order to enable MERCK to enjoy, as currently enjoyed by MERCK as at
the EFFECTIVE DATE, the licenses granted by ONCOTHYREON to MERCK under this
AGREEMENT; and
	 
	 	12.6.1.6	 	to ONCOTHYREON’s knowledge after due inquiry, the ICRT LICENSE and the
DANA-FARBER LICENSE are in full force and effect and ONCOTHYREON has no
knowledge of any breach or action by ONCOTHYREON which might give rise to a
breach under such licenses.

Section 12.7 No Further Representations or Warranties

Except as expressly provided in this article 12 or any other provision of this AGREEMENT, or in the
Asset Purchase Agreement, neither party makes any representation or warranty of any kind to the
other party, express or implied.

Section 12.8 Survival of Representations and Warranties

The representations and warranties contained in this AGREEMENT shall survive the EFFECTIVE DATE, as
applicable, for a period of one (1) year.

ARTICLE 13

INDEMNIFICATION

Section 13.1 Indemnification by ONCOTHYREON

Subject to the terms and conditions of this AGREEMENT, ONCOTHYREON shall indemnify and hold MERCK
(and any affiliated corporation and their respective officers, directors, shareholders, employees
and agents) (collectively, the “MERCK INDEMNITEES”), free and harmless from any and all claims,
demands, liabilities, losses, actions or causes of actions, and any and all expenses associated
therewith (including, without limiting the generality of the foregoing, reasonable defense costs
and attorney’s fees), arising out of or in connection with, or that are the result of, or are
otherwise related to: (i) actions and proceedings brought by any regulatory or other authority
against any of the MERCK INDEMNITEES concerning PRODUCT, for or on account of the alleged
unapproved or unauthorized introduction by ONCOTHYREON, its AFFILIATES or their respective agents
of PRODUCT in interstate or intrastate commerce anywhere in the world; (ii) any claim, complaint,
suit, proceeding or cause of action against any of the MERCK INDEMNITEES alleging physical injury,
including death as a result of the acts or omissions of ONCOTHYREON, its AFFILIATES or their
respective employees and agents, except to the extent attributable to any one or more of the MERCK
INDEMNITEES; (iii) ONCOTHYREON’s, its AFFILIATES’ or their respective agents’ non-compliance with
any applicable laws or regulations, except to the extent attributable to any one or more of the
MERCK INDEMNITEES; (iv) any failure of ONCOTHYREON to perform, in

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

 

40

whole or in part, any of its obligations hereunder, except to the extent attributable to any one or
more of the MERCK INDEMNITEES; (v) for the period specified in section 12.8, any breach by
ONCOTHYREON of any of its representations or warranties under this AGREEMENT; or (vi) any breach by
ONCOTHYREON or its AFFILIATES of the THIRD PARTY LICENSES which materially adversely affects
MERCK’s rights under this AGREEMENT, except to the extent attributable to any one or more of the
MERCK INDEMNITEES.

Section 13.2 Indemnification by MERCK

Subject to the terms and conditions of this AGREEMENT, MERCK shall indemnify and hold ONCOTHYREON
(and any affiliated corporation and their respective officers, directors, shareholders, employees
and agents) (the “ONCOTHYREON INDEMNITEES”), free and harmless from any and all claims, demands,
liabilities, losses, actions or causes of actions, and any and all expenses associated therewith
(including, without limiting the generality of the foregoing, reasonable defense costs and
attorney’s fees), arising out of or in connection with, or that are the result of, or are otherwise
related to: (i) actions and proceedings brought by any regulatory authority against any of the
ONCOTHYREON INDEMNITEES concerning PRODUCT, for or on account of the alleged unapproved or
unauthorized introduction by MERCK, its AFFILIATES or their respective distributors, sublicensees
and agents of PRODUCT in interstate or intrastate commerce anywhere in the world; (ii) any claim,
complaint, suit, proceeding or cause of action against any of the ONCOTHYREON INDEMNITEES alleging
physical injury, including death as a result of the acts or omissions of MERCK, its AFFILIATES or
their respective employees, distributors, sublicensees and agents, except to the extent
attributable to any one or more of the ONCOTHYREON INDEMNITEES; (iii) MERCK’s, its AFFILIATES’ or
their respective distributors’, sublicensee’s or agents’ non-compliance with any applicable laws or
regulations, except to the extent attributable to any one or more of the ONCOTHYREON INDEMNITEES;
(iv) any failure of MERCK to perform, in whole or in part, any of its obligations hereunder, except
to the extent attributable to any one or more of the ONCOTHYREON INDEMNITEES; (v) MERCK’s, its
AFFILIATES’ or their respective distributors’, sublicensees’, contract manufacturers’ or agents’
manufacture, marketing and/or SALE of PRODUCT, except to the extent attributable to any one or more
of the ONCOTHYREON INDEMNITEES; or (vi) for the period specified in section 12.8, any breach by
MERCK of any of its representations or warranties under this AGREEMENT.

Section 13.3 Procedure

The indemnified party shall give prompt written notice to the indemnifying party(ies) of any suits,
claims or demands by third parties or the indemnified party which may give rise to any loss for
which indemnification may be required under this article 13; provided, however, that failure to
give such notice shall not impair the obligation of the indemnifying party to provide
indemnification hereunder except if and to the extent that such failure materially impairs the
ability of the indemnifying party to defend the applicable suit, claim or demand. The indemnifying
party shall be entitled to assume the defense and control of any suit, claim or demand of any third
party at its own cost and expense; provided, however, that the other party shall have the right to
be represented by its own counsel at its own cost in such matters. In the event that the
indemnifying party shall decline to assume control of any such suit, claim or demand, the party
entitled to indemnification shall be entitled to assume such control, conduct the defense of, and
settle such suit, claim or action, all at the sole cost and expense of the indemnifying party.
Neither the indemnifying party nor the indemnified party shall settle or

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

41

dispose of any such matter in any manner which would adversely impact the rights or interests of
the other party without the prior written consent of the indemnified party, which shall not be
unreasonably withheld. Each party shall cooperate with the other party and its counsel in the
course of the defense of any such suit, claim or demand, such cooperation to include using
reasonable efforts to provide or make available documents, information and witnesses.

ARTICLE 14

MISCELLANEOUS

Section 14.1 Force Majeure

Any delay in the performance of any of the obligations of either party (except for the payment of
money) shall not be considered a breach of this AGREEMENT and the time required for performance
shall be extended for a period equal to the period of such delay, provided that such delay has been
caused by or is the result of (including without limitation in relation to third party contractors
and suppliers) any act of God, acts of the public enemy; insurrections; riots; embargoes; labour
disputes such as strikes, lockouts or boycotts; fires; explosions; floods; earthquakes; mudslides;
or other unforeseeable causes beyond the control of the party so affected. The party so affected
shall give prompt notice to the other party of such cause, and shall take whatever reasonable steps
are necessary to relieve the effect of such cause as rapidly as reasonable.

Section 14.2 Independent Contractor

Execution of each party’s responsibilities under this AGREEMENT is solely under the direction and
control of each respective party as an independent contractor, and not as an employee or agent of
the other party.

Section 14.3 Survival

Such provisions of this AGREEMENT that, by their nature, would be expected to survive termination
of this AGREEMENT, including without limitation sections 7.3, 7.5, 11.3, 11.4, 11.5, 11.6, 14.6,
14.9 and 14.14 and articles 8 and 13 shall survive any such termination.

Section 14.4 Notice

Whenever any notice is to be given hereunder, it shall be in writing and shall be deemed received
on the day delivered, if delivered by courier on a business day, or if sent by first-class
certified or registered mail, postage prepaid, to the following addresses:

ONCOTHYREON:

Biomira Management, Inc.

2601 Fourth Avenue, Suite 500

Seattle WA 98121

United States of America

Attention: President

Facsimile: (206) 801-2101

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

42

With a copy to:

Oncothyreon Inc.

2601 Fourth Avenue, Suite 500

Seattle WA 98121

United States of America

Attention: President

Facsimile: (206) 801-2101

MERCK:

Merck KGaA

Frankfurter Strasse 250

D-64293 Darmstadt

Germany

Attention: Merck Serono Legal Department

Facsimile: +49-6151-72-2373

With a copy to

Merck Serono S.A Geneva

9 Chemin des Mines, 1202 Geneva

Switzerland

Facimile: +41224143660

Section 14.5 Waivers

No waiver of any term, provision, or condition of this AGREEMENT, whether by conduct or otherwise,
in any one or more instances, shall be deemed to be construed as a further or continuing waiver of
any such term, provision, or condition of this AGREEMENT unless reduced to writing signed by an
authorized representative of each party.

Section 14.6 Applicable Law

This agreement shall be construed under the substantive laws of England, without reference to its
conflicts of laws provisions.

Section 14.7 Dispute Resolution

Should any dispute arise between the parties concerning this AGREEMENT, the parties agree to first
attempt to resolve the dispute in good faith. If within fifteen (15) days of one party providing
written notice of such dispute to the other party such dispute is not resolved, then the parties
agree to continue to attempt to resolve the dispute in good faith through meetings between a member
of MERCK’s Executive Management Board and the President of ONCOTHYREON before resorting to any
other forum for a remedy. If resolution of the dispute is not reached between the Presidents
within twenty (20) days of either party submitting such dispute in writing to the Presidents, then
the parties shall within the next following fifteen (15) day period initiate binding arbitration in
London, England under the rules of the International Chamber of Commerce. The party desiring
arbitration shall nominate one (1) arbitrator and shall

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

43

notify the other party in writing of such nomination. Such other party shall, within ten (10) days
after receiving such notice, nominate an arbitrator and the two (2) arbitrators shall select a
third arbitrator of the arbitration tribunal to act jointly with them. The parties will act
reasonably and in good faith to select arbitrators who are objective and who are suitably qualified
by education or professional experience to deal with the matters which are the subject of the
arbitration.

Section 14.8 Assignment

The parties agree that this AGREEMENT is personal in nature and, except for transfer by ONCOTHYREON
to any of its AFFILIATES, this AGREEMENT may not be assigned or otherwise transferred, nor may any
right or obligations hereunder be assigned or transferred directly or indirectly by either party,
whether voluntary, by operation of law or otherwise, without the written consent of the other
party, such consent not to be unreasonably withheld. In connection with ONCOTHYREON determining
whether to consent to an assignment, the parties agree that ONCOTHYREON shall be deemed to be
acting reasonably if it withholds its consent in circumstances where the proposed assignee is not a
corporation of equal or greater financial resources, marketing strength and expertise (including in
the cancer area), and stature in the pharmaceutical industry as MERCK. Any purported assignment in
violation of this section 14.8 shall be void. Notwithstanding the foregoing, either party may,
without such consent, assign or novate this AGREEMENT and its rights and obligations hereunder in
connection with the transfer or sale of all or substantially all of its business, through merger,
consolidation or change in control or similar transaction after first giving the other party
written notice of such event. Pursuant to any such assignment, any permitted assignee shall assume
all rights of the assignor under this AGREEMENT, and pursuant to any such novation, any permitted
novatee shall assume all rights and obligations of the novator under this AGREEMENT.

Section 14.9 Currency

All payments to be made under this AGREEMENT shall be made in United States dollars. The currency
in which NET SALES were invoiced shall be converted to United States dollars on the date of payment
of the royalty due using the applicable commercial rate of exchange for buying US dollars with the
currency that is the average of the closing buying rates for such currency for the quarter for
which such payments are due, quoted as local currency per US $1, as established and published by
the European Central Bank.

Section 14.10 Payment of taxes

Each of ONCOTHYREON and MERCK shall be responsible for any and all taxes and other similar levies
or charges properly assessed against payments received by such party from the other party under
this AGREEMENT. If applicable laws or regulations require that taxes be withheld on such payments,
the withholding party will in a timely manner notify the other party in writing specifying the
details thereof and shall:

	 	14.10.1	 	deduct those taxes from the amount of such payment due to the receiving party,
	 
	 	14.10.2	 	pay the taxes to the proper taxing authority in a timely manner, and
	 
	 	14.10.3	 	send proof of payment to the receiving party within sixty (60) days following that
payment.

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

44

The parties agree to cooperate to reduce the amount of any such deductions and to obtain the
benefit of any tax treaty with respect to such deductions. Further, the withholding party shall
cooperate with the receiving party in obtaining for the receiving party a credit or refund for any
such taxes, levies or charges. Neither party shall be required under this concluding paragraph of
section 14.10 to act in a manner which is financially detrimental from a taxation perspective to
such party.

Section 14.11 Interest

Any late payments of any nature under this AGREEMENT shall bear interest, running from the date
such payment was due until such payment is made in full, at a rate per annum equal to the average
three (3) month US dollar LIBOR rate (as published from time to time by Reuters) plus one percent
(1%).

Section 14.12 Sublicensees

In addition to the requirements of sections 2.1 and 2.3 of this AGREEMENT, in the event MERCK
utilizes any AFFILIATE or third party to distribute PRODUCT (directly or indirectly) for MERCK in
the TERRITORY or otherwise sublicenses any of the licensed rights under this AGREEMENT, the
agreement with such AFFILIATE or third party shall include an obligation for such third party to
comply with the provisions of this AGREEMENT on the same basis as if such SALES were made by MERCK,
and MERCK shall for all purposes under this AGREEMENT treat the net sales of PRODUCT of the
sublicensee as NET SALES of MERCK.

Section 14.13 Limitation

Notwithstanding any other provision to the contrary in this AGREEMENT, other than with respect to
applicable third party product liability and patent infringement claims, the maximum aggregate
liability of ONCOTHYREON under this AGREEMENT shall not exceed the amounts paid by MERCK to
ONCOTHYREON up to the time in question under this AGREEMENT (including, for greater certainty,
payments by MERCK under this AGREEMENT with respect to shared costs, equity purchases and
milestones) and any preceding agreement between the parties relating to the PRODUCT. Neither party
shall have any liability to the other party or any other person pursuant to this AGREEMENT for any
special, indirect or consequential damages, including but not limited to loss of profits, loss of
business opportunities or loss of business investment.

Section 14.14 Severability

If any provision of this AGREEMENT is held to be illegal or unenforceable, that provision shall be
limited to the minimum extent necessary or, if necessary, eliminated, so that this AGREEMENT shall
otherwise remain enforceable and in full force and effect

Section 14.15 Integration Clause

Except for the ASSET PURCHASE AGREEMENT, this AGREEMENT is the sole agreement with respect to the
subject matter hereof, and supersedes all proposals, negotiations, conversations, discussions,
agreements (including the 2006 COLLABORATION AGREEMENT and the 2006 SUPPLY AGREEMENT) and/or
representations, whether oral or written, including any industry custom or past dealing between the
parties relating to the subject matter of this AGREEMENT. The parties agree that any and all obligations between the parties that are outside the
terms of this  AGREEMENT and that relate to the subject matter of this

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

45

 AGREEMENT that preceded the
EFFECTIVE DATE of this AGREEMENT have been satisfactorily executed or are null and void.

Section 14.16 U.S. Dollars

Unless otherwise provided, any reference in this AGREEMENT to dollars shall be to U.S. dollars.

Section 14.17 Amendment of Agreement

No change, modification, extension, termination, waiver or other amendment of this AGREEMENT or any
of the provisions contained herein, shall be valid unless made in writing and signed by a duly
authorized representative of each party.

Section 14.18 Third Parties

A person who is not a party to this AGREEMENT has no rights under the Contracts (Rights of Third
Parties) Act 1999 to enforce any term of this AGREEMENT.

Section 14.19 No Further Representations or Warranties

Each party acknowledges that it has not relied on or been induced to enter this AGREEMENT by a
representation or warranty other than those expressly set out in this AGREEMENT. A party is not
liable to the other party for a representation or warranty that is not set out in this AGREEMENT,
including any warranty implied by statute.

Section 14.20 Non-Solicitation

During the term of this AGREEMENT, without the prior written consent of the other party, neither
party shall knowingly solicit for hire any existing employee of the other party.

Section 14.21 Counterparts

This AGREEMENT may be executed in several counterparts, each of which when so executed shall be
deemed to be an original and shall have the same force and effect as an original but such
counterparts together shall constitute but one and the same instrument.

This AGREEMENT is agreed to and accepted by:

	 	 	 	 	 	 	 	 	 
	Merck KGaA	 	 	 	Biomira Management Inc.
	 
	 	 	 	 	 	 	 	 
	By:

	 	/s/ Andreas Stickler
	 	 
	 	By:
	 	/s/ Robert L. Kirkman, M.D.
	 

	 	 
	 	 	 	 	 	 
	 

	 	Title: Head of M&A
	 	 	 	 
	 	Title: President & CEO
	 

	 	 
	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	AND
	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	By:

	 	/s/ Jens Eckhardt	 	 	 	 	 	 
	 

	 	 	 	 	 	 	 	 
	 	 	Title: Associate General Counsel	 	 	 	[IN DUPLICATE]
	 

	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	 	 	 

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

46

APPENDIX 1

CORE PATENT COUNTRIES

[+]

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

47

APPENDIX 2

ONCOTHYREON KNOW-HOW

[+] [Redaction continues for two pages]

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

48

APPENDIX 3

ONCOTHYREON PATENT RIGHTS

[+]

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

49

APPENDIX 4

PROTOCOL FOR PHASE III CLINICAL TRIAL

OF BLP25 FOR NON-SMALL CELL LUNG CANCER

[+]

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

50

APPENDIX 5

TRADEMARKS

TRADE-MARK STATUS FOR THEXOPE

(UPDATED DECEMBER 18, 2008)

	 	 	 	 	 	 	 	 	 	 	 
	COUNTRY/	 	 	 	FILING	 	FILING/REGISTRATION	 	 	 	GOODS
	REGISTRAR	 	APPLICANT	 	DATE	 	NUMBER	 	STATUS	 	REGISTERED
	U.S.

	 	Biomira Inc.
Assigned to
Oncothyreon Canada
Inc. effective Dec
10, 2007 since we
could not seek an
extension of time
to file a DOU
unless the current
owner made such a
request. Biomira
Inc. was not longer
an entity as it had
merged and changed
its name.
	 	January 26, 2007
	 	77/092,486
	 	Initial U.S.
application lapsed
as use had not
commenced before
deadline for filing
a declaration of
use and payment.
Based on
instructions, we
have re-filed an
application in the
U.S. on an
intent-to use
basis.

Mark was published
in the Official
Gazette on November
6, 2007.

Any third party
will have 30 days
within which to
oppose (extendable
out to 120 days
from November 6,
2007 without
consent and an
additional 60 days
with consent)
	 	Immunological
preparations used
for the prevention
and treatment of
cancer.
	 
	 

	 	 	 	 	 	 	 	Mark was allowed
and a DOU must be
filed by January
29, 2009	 	 

TRADE-MARK STATUS FOR JEXAVE

(UPDATED DECEMBER 18, 2008)

	 	 	 	 	 	 	 	 	 	 	 
	COUNTRY/	 	 	 	FILING	 	FILING/REGISTRATION	 	 	 	GOODS
	REGISTRAR	 	APPLICANT	 	DATE	 	NUMBER	 	STATUS	 	REGISTERED
	U.S.

	 	Biomira Inc.
Assigned to
Oncothyreon Canada
Inc. effective Dec
10, 2007 since we
could not seek an
extension of time
to file a DOU
unless the current
owner made such a
request. Biomira
Inc. was not longer
an entity as it had
merged and changed
its name.
	 	January 26, 2007
	 	77/092,474
	 	Initial U.S.
application lapsed
as use had not
commenced before
deadline for filing
a declaration of
use and payment.
Based on
instructions, we
have re-filed an
application in the
U.S. on an
intent-to use
basis.

Mark was published
in the Official
Gazette on November
6, 2007.

Any third party
will have 30 days
within which
	 	Immunological
preparations used
for the prevention
and treatment of
cancer.

 

51

	 	 	 	 	 	 	 	 	 	 	 
	COUNTRY/	 	 	 	FILING	 	FILING/REGISTRATION	 	 	 	GOODS
	REGISTRAR	 	APPLICANT	 	DATE	 	NUMBER	 	STATUS	 	REGISTERED
	 

	 	 	 	 	 	 	 	to
oppose (extendable
out to 120 days
from November 6,
2007 without
consent and an
additional 60 days
with consent)

Mark was allowed
and a DOU must be
filed by January
29, 2009.	 	 

TRADE-MARK STATUS FOR SIATOPE

(UPDATED DECEMBER 18, 2008)

	 	 	 	 	 	 	 	 	 	 	 
	COUNTRY/	 	 	 	FILING	 	FILING/REGISTRATION	 	 	 	GOODS
	REGISTRAR	 	APPLICANT	 	DATE	 	NUMBER	 	STATUS	 	REGISTERED
	Benelux

	 	Biomira B.V.
	 	April 5, 2005
	 	763778
	 	Registered and
protected until
March 16, 2015.

Name change
submitted and
recorded.
	 	Pharmaceutical and
veterinary
preparations.
	 
	 	 	 	 	 	 	 	 	 	 
	United States

	 	Biomira Inc.
Assigned to
Oncothyreon Canada
Inc. effective Dec
10, 2007 since we
could not seek an
extension of time
to file a DOU
unless the current
owner made such a
request. Biomira
Inc. was not longer
an entity as it
	 	January 26, 2007.
Notice of Allowance
January 29, 2008
	 	Serial number 77/092,448
	 	Office Action was
issued requiring a
clarification of
goods. The earlier
SIATOPE application
was abandoned on
February 4, 2007
due to failure to
file a declaration
of use after the
last extension of
time. Based on
instructions, we
re-filed on an
intent to use
	 	Immunological
preparations used
for the prevention
and treatment of
cancer.

 

52

	 	 	 	 	 	 	 	 	 	 	 
	COUNTRY/	 	 	 	FILING	 	FILING/REGISTRATION	 	 	 	GOODS
	REGISTRAR	 	APPLICANT	 	DATE	 	NUMBER	 	STATUS	 	REGISTERED
	 

	 	had merged and
changed its name.
	 	 	 	 	 	basis.

Mark was published
in the Official
Gazette on November
6, 2007.

Any third party
will have 30 days
within which to
oppose (extendable
out to 120 days
from November 6,
2007 without
consent and an
additional 60 days
with consent)

Mark was allowed
and a DOU must be
filed by July 29,
2008. Extension
granted to January
29, 2009	 	 

TRADE-MARK STATUS FOR STENVAX

(UPDATED DECEMBER 18, 2008)

	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	STATUS AND	 	 
	COUNTRY/	 	 	 	FILING	 	FILING/REGISTRATION	 	SPECIAL	 	GOODS
	REGISTRAR	 	APPLICANT	 	DATE	 	NUMBER	 	NOTES	 	REGISTERED
	EU

	 	Biomira B.V.
	 	06/09/05

Priority date:

16/03/05 based
 on
Benelux 

application
	 	004620258
	 	Certificate issued.
Trade-mark
protected until
September 6, 2015.

Name change to
Merck KGaA
recorded.
	 	Pharmaceutical and
veterinary
preparations.
	 
	 	 	 	 	 	 	 	 	 	 
	Benelux

	 	Biomira B.V.
	 	06/09/05
	 	Certificate number

763776
	 	Certificate issued.
Trade-mark
protected until
March 16, 2015.

Name change
recorded.
	 	Pharmaceutical and
veterinary
preparations.

 

53

	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	STATUS AND	 	 
	COUNTRY/	 	 	 	FILING	 	FILING/REGISTRATION	 	SPECIAL	 	GOODS
	REGISTRAR	 	APPLICANT	 	DATE	 	NUMBER	 	NOTES	 	REGISTERED
	IR — WIPO

	 	Biomira B.V.
	 	06/09/05
	 	IR Number 863163
	 	Certificate issued.

Name change to
Merck KGaA
recorded.

Protected in 36
countries (see
attached) until
September 6, 2015
as per instructions
March 3 and August
30, 2005.

Singapore office
advised the mark is
protected.

North Korean office
extends protection.

South Korean office
issued a
preliminary
refusal. Response
submitted and
refusal lifted.

 Certificate issued.

Japan notified that
mark is registered.

Australia notified
that mark is
registered

Norway notified
that protection
extended.

Turkey notified
that protection
extended

Romania —
	 	Pharmaceutical and
veterinary
preparations.

(except in Romania,
“pharmaceutical
products” only).

 

54

	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	STATUS AND	 	 
	COUNTRY/	 	 	 	FILING	 	FILING/REGISTRATION	 	SPECIAL	 	GOODS
	REGISTRAR	 	APPLICANT	 	DATE	 	NUMBER	 	NOTES	 	REGISTERED
	 

	 	 	 	 	 	 	 	preliminary refusal
of protection based
on “STAMVAX”
registered for
Veterinary
products.
Protection extended
for “pharmaceutical
products” only.

Georgia notified
that protection
extended.

U.S.A. —
preliminary
objection overcome.
Mark registered
March 11, 2008.
Certificate
received.

Montenegro protected	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	United States

	 	Biomira B.V.
	 	 	 	76/504,953 (abandoned)

Registration 3,395,103

(subsequent

designation via WIPO)

79/034,455
	 	Initial U.S.
application
abandoned for
failure to file a
DOU by Feb 3, 2007.

Subsequent
designation via
WIPO of USA
registered March
11, 2008.
Certificate
received.
	 	Immunological
pharmaceutical
preparations used
for the prevention
and treatment of
cancer.
	 
	 	 	 	 	 	 	 	 	 	 
	Canada

	 	Biomira Inc.
	 	14/12/05
	 	1283920
	 	Allowed.
Declaration of use
and fee must be
submitted by
	 	Immunological

pharmaceutical

preparations used

for the prevention

or treatment of

 

55

	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	STATUS AND	 	 
	COUNTRY/	 	 	 	FILING	 	FILING/REGISTRATION	 	SPECIAL	 	GOODS
	REGISTRAR	 	APPLICANT	 	DATE	 	NUMBER	 	NOTES	 	REGISTERED
	 

	 	 	 	 	 	 	 	June 14, 2009
	 	cancer.
	 
	 	 	 	 	 	 	 	 	 	 
	New Zealand

	 	Biomira B.V
	 	08/09/05
	 	735373
	 	Certificate
received.
Trade-mark
protected until
March 16, 2015.

Name change
recorded.
	 	Pharmaceutical and
veterinary
preparations.
	 
	 	 	 	 	 	 	 	 	 	 
	South Africa

	 	Biomira B.V.
	 	07/09/05
	 	2005/18911
	 	Notice of Allowance
granted. To be
published January
29, 2009, followed
by a 3 month
opposition period.

Name change recorded	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	Argentina

	 	Biomira Europe B.V.
	 	14/09/05
	 	2.174.144
	 	Published November
9, 2005. Opposed
by owners of
OPENVAS. Opponent
has withdrawn
opposition based on
an agreement with
local counsel to
limit our list of
goods and services.

Registered until
August 9, 2017.
Renewable for 10
years. Must use in
last five years
before renewal and
subject to
cancellation if not
used during a 5
year period.
	 	Pharmaceutical
preparations for
human use,
excluding
pharmaceuticals for
the treatment of
erectile
dysfunction.

This description is
based on
negotiations with
the opponent,
LABORATORIO KAMPEL.

Certificate
Received.

 

56

	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	STATUS AND	 	 
	COUNTRY/	 	 	 	FILING	 	FILING/REGISTRATION	 	SPECIAL	 	GOODS
	REGISTRAR	 	APPLICANT	 	DATE	 	NUMBER	 	NOTES	 	REGISTERED
	Bolivia

	 	Biomira Europe B.V.
	 	15/09/05
	 	120046
	 	Registered until
March 2, 2017
	 	Pharmaceutical and
veterinary
preparations.
	 
	 	 	 	 	 	 	 	 	 	 
	Brazil

	 	Biomira BV
	 	18/10/05
	 	827760299
	 	Published in
Gazette.
Instructions
provided to proceed
to registration May
2008

Effectively
registered as of
July 08; waiting
for certificate
	 	Pharmaceutical and
veterinary
preparations.
	 
	 	 	 	 	 	 	 	 	 	 
	Chile

	 	Biomira Europe B.V.
	 	15/09/05
	 	750.682
	 	Certificate
received.
Trade-mark
protected until
February 14, 2016.

Priority claim not
reflected. Issue
being resolved.

A registered mark
must be shown with
the words “Marca
Registrada” or the
initials M.R. or ®
	 	Pharmaceutical and
veterinary
preparations.
	 
	 	 	 	 	 	 	 	 	 	 
	Colombia

	 	Biomira Europe B.V.
	 	15/09/05
	 	05-093.461
	 	Registered until
June 14, 2016

Must be used within
3 years of
registration in one
of the countries of
the Andean
Community Pact to
avoid cancellation
by a third party
for non-use
	 	Pharmaceutical and
veterinary
preparations.

 

57

	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	STATUS AND	 	 
	COUNTRY/	 	 	 	FILING	 	FILING/REGISTRATION	 	SPECIAL	 	GOODS
	REGISTRAR	 	APPLICANT	 	DATE	 	NUMBER	 	NOTES	 	REGISTERED
	Ecuador

	 	Biomira Europe B.V.
	 	9/9/05
	 	161784
	 	Certificate
received.
Trade-mark
protected until
October 12, 2016
	 	Pharmaceutical,
veterinary and
sanitary products;
dietary substances
for medical use,
food for babies;
poultices, material
for priests
(dressings)
materials to fill
the teeth and for
dental molds;
disinfectant;
products for the
destruction of
harmful animals;
fungicides,
herbicides.
	 
	 	 	 	 	 	 	 	 	 	 
	Mexico

	 	Biomira B.V.
	 	19/09/05 (due to a
national holiday on
the
15th)
	 	918964
	 	Certificate
received.
Trade-mark
protected until
September 19, 2015.
	 	Pharmaceutical and
veterinary
preparations.
	 
	 	 	 	 	 	 	 	 	 	 
	Peru

	 	Biomira Europe B.V.
	 	09/09/05
	 	254052-2005
	 	Certificate
received.
Trade-mark
protected until May
5, 2016.
	 	Pharmaceutical
preparations and
veterinary
medicine.
	 
	 	 	 	 	 	 	 	 	 	 
	Venezuela

	 	Biomira Europe B.V.
	 	13/09/05
	 	20170-05

P-274382
	 	Cleared for
registration
October 25, 2006.
It may take up to
two years until the
registration
certificate is
issued.
	 	Pharmaceutical and
veterinary
preparations.
	 
	 	 	 	 	 	 	 	 	 	 
	Hong Kong

	 	Biomira Europe B.V.
	 	10/09/05
	 	300493083
	 	Certificate
received.

Trade-mark
protected until
September 9,
	 	Pharmaceutical and
veterinary
preparations.

 

 

58

	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	STATUS AND	 	 
	COUNTRY/	 	 	 	FILING	 	FILING/REGISTRATION	 	SPECIAL	 	GOODS
	REGISTRAR	 	APPLICANT	 	DATE	 	NUMBER	 	NOTES	 	REGISTERED
	 

	 	 	 	 	 	 	 	2015. 

 — must be
used within 3 years
or can be attacked
for non-use

Name change to
Merck KGaA
recorded.	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	India

	 	Biomira Europe B.V.
	 	16/09/05
	 	1385354
	 	Filed. Objections
raised by
Trade-mark office
regarding
confusingly similar
names. It appears
to be routine
practice in India
for the Office to
raise an objection
to any application
that may be
remotely similar to
existing marks.
Local counsel has
filed compelling
objections to the
Examiner’s report
and are awaiting a
response regarding
a hearing date.
Hearing occurred
and arguments
accepted. Mark
will now be
published.
	 	Pharmaceutical and
veterinary
preparations.
	 
	 	 	 	 	 	 	 	 	 	 
	Indonesia

	 	Biomira B.V.
	 	14/12/05
	 	D00.2005.019211
	 	Registered until
December 14, 2015.
	 	Pharmaceutical and
veterinary
preparations.
	 
	 	 	 	 	 	 	 	 	 	 
	Israel

	 	Biomira B.V.
	 	7/09/05
	 	183511
	 	Registered until
September 7,
	 	Pharmaceutical

preparations for

 

59

	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	STATUS AND	 	 
	COUNTRY/	 	 	 	FILING	 	FILING/REGISTRATION	 	SPECIAL	 	GOODS
	REGISTRAR	 	APPLICANT	 	DATE	 	NUMBER	 	NOTES	 	REGISTERED
	 

	 	 	 	 	 	 	 	2015

Name change
recorded.
	 	the prevention and
treatment of
cancer.
	 
	 	 	 	 	 	 	 	 	 	 
	Lebanon

	 	Biomira BV
	 	13/09/05
	 	103792
	 	Certificate issued.
Protected until
September 13, 2020.

Name change
recorded.
	 	Pharmaceutical and
veterinary
preparations.
	 
	 	 	 	 	 	 	 	 	 	 
	Malaysia

	 	Biomira Europe B.V.
	 	09/09/05
	 	05015148
	 	Registered until
March 16, 2015.
Must use mark by
November 2010 at
the latest and mark
is subject to
cancellation if not
used during a three
year period.
	 	Pharmaceutical and
veterinary
preparations.

Certificate
received.
	 
	 	 	 	 	 	 	 	 	 	 
	Taiwan

	 	Biomira Europe B.V.
	 	08/09/05
	 	094043194
	 	Certificate issued.
Protected until
June 15, 2016.
Should be used
within 3 years of
registration
	 	Pharmaceutical and
veterinary
preparations.
	 
	 	 	 	 	 	 	 	 	 	 
	U.A. Emirates

	 	Biomira Europe B.V.
	 	14/09/2005
	 	73130
	 	Registered until
September 14, 2015
	 	Pharmaceutical
preparations and
veterinary.

TRADE-MARK STATUS FOR STIMRIS

(UPDATED DECEMBER 18, 2008)

	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	STATUS AND	 	 
	COUNTRY/	 	 	 	FILING	 	FILING/REGISTRATION	 	SPECIAL	 	GOODS
	REGISTRAR	 	APPLICANT	 	DATE	 	NUMBER	 	NOTES	 	REGISTERED
	EU

	 	Biomira B.V.
	 	16/03/2005
	 	004341442
	 	Certificate issued
(awaiting receipt).

Protected in
	 	Pharmaceutical and
veterinary
preparations.

 

60

	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	STATUS AND	 	 
	COUNTRY/	 	 	 	FILING	 	FILING/REGISTRATION	 	SPECIAL	 	GOODS
	REGISTRAR	 	APPLICANT	 	DATE	 	NUMBER	 	NOTES	 	REGISTERED
	 

	 	 	 	 	 	 	 	 25 EU
member states until 

March 16, 2015. 

Name change to
Merck KGaA
recorded.	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	Benelux

	 	Biomira B.V.
	 	12/08/2005
	 	Certificate number

763779
	 	Certificate issued.
Trade-mark
protected until
March 16, 2015.

Name change
recorded.
	 	Pharmaceutical and
veterinary
preparations.
	 
	 	 	 	 	 	 	 	 	 	 
	IR — WIPO

	 	Biomira B.V.
	 	12/08/2005
	 	IR number 863224
	 	Certificate issued.

Name change to
Merck KGaA
recorded.

Protected in 51
countries (see
attached) until
August 12, 2015 as
per instructions
March 3 and August
30, 2005.

Singapore office
advised the mark is
protected.

North Korean office
extends protection.

South Korean office
issued a
preliminary
refusal. Response
submitted and
	 	Pharmaceutical and
veterinary
preparations.

 

 

61

	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	STATUS AND	 	 
	COUNTRY/	 	 	 	FILING	 	FILING/REGISTRATION	 	SPECIAL	 	GOODS
	REGISTRAR	 	APPLICANT	 	DATE	 	NUMBER	 	NOTES	 	REGISTERED
	 

	 	 	 	 	 	 	 	refusal lifted.
Certificate issued

Japan-Certificate
issued.

Australia notified
that mark is
registered and
protected until
August 12, 2015.

Norway notified
that protection
extended.

Turkey notified
that protection
extended

Georgia extends
protection.

Syria extends
protection.

Armenia extends
protection.

U.S.A. —
preliminary
objection overcome.
Mark registered
March 11, 2008.

Certificate
received.

Montenegro protected	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	Netherlands

Antilles

	 	Biomira Europe B.V.
	 	16/03/2005
	 	11278
	 	Registered.

May 18, 2005.
Certificate
	 	Pharmaceutical and
veterinary
preparations

 

 

62

	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	STATUS AND	 	 
	COUNTRY/	 	 	 	FILING	 	FILING/REGISTRATION	 	SPECIAL	 	GOODS
	REGISTRAR	 	APPLICANT	 	DATE	 	NUMBER	 	NOTES	 	REGISTERED
	 

	 	 	 	 	 	 	 	issued.
Protected until
March 16, 2015.	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	United States

	 	Biomira B.V.
	 	08/04/2003
	 	Serial number

76/504,971

(abandoned)

Registration

3,395,128

(subsequent

designation via

WIPO) Serial

79/035,623
	 	Requires filing of
a Declaration of
Use.
5th and
final extension
obtained until Feb
3, 2007. Abandoned.

Certificate of
Registration
received.
Subsequent
designation via
WIPO of USA
registered March
11, 2008 based on
filing of
Declaration of
Intent to Use
	 	Immunological
pharmaceutical
preparations used
for the prevention
and treatment of
cancer.
	 
	 	 	 	 	 	 	 	 	 	 
	Canada

	 	Biomira Inc.
	 	10/03/2005
	 	1250588
	 	Application was
allowed. A DOU
needs to be filed.
An extension of
time was granted to
March 2009
	 	Immunological
pharmaceutical
preparations used
for the prevention
or treatment of
cancer.
	 
	 	 	 	 	 	 	 	 	 	 
	New Zealand

	 	Biomira B.V.
	 	08/09/05
	 	735372
	 	Certificate issued.
Trade-mark
protected until
March 16, 2015.

Name change
recorded.
	 	Pharmaceutical and
veterinary
preparations
	 
	 	 	 	 	 	 	 	 	 	 
	South Africa

	 	Biomira B.V.
	 	07/09/05
	 	2005/18910
	 	Application

accepted for

advertisement for

Journal	 	 

 

 

63

	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	STATUS AND	 	 
	COUNTRY/	 	 	 	FILING	 	FILING/REGISTRATION	 	SPECIAL	 	GOODS
	REGISTRAR	 	APPLICANT	 	DATE	 	NUMBER	 	NOTES	 	REGISTERED
	 

	 	 	 	 	 	 	 	March 26,
2008. 3 month
opposition period
follows.

Name change
recorded.	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	Argentina

	 	Biomira Europe B.V.
	 	14/09/05
	 	2.618.031
	 	Published November
9, 2005.

TM registered until
November 26, 2016.
Certificate
received
	 	Pharmaceutical
preparations and
veterinary
preparations

Biomira BV filed
opposition against
trade-mark SIMRAS
owned by Ferrer
Internacional SA.
Opponent has not
been in touch with
our local counsel
as of May 8, 2008
and we are waiting
to see whether they
will restrict the
list of goods and
services in their
application.
	 
	 	 	 	 	 	 	 	 	 	 
	Bolivia

	 	Biomira Europe B.V.
	 	15/09/05
	 	120047
	 	Registered until
March 2, 2017
	 	Pharmaceutical and
veterinary
preparations
	 
	 	 	 	 	 	 	 	 	 	 
	Brazil

	 	Biomira BV
	 	18/10/05
	 	827760310
	 	Published in
Gazette.
Instructions
provided to proceed
to registration May
08

Effectively
	 	Pharmaceutical and
veterinary
preparations.

 

 

64

	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	STATUS AND	 	 
	COUNTRY/	 	 	 	FILING	 	FILING/REGISTRATION	 	SPECIAL	 	GOODS
	REGISTRAR	 	APPLICANT	 	DATE	 	NUMBER	 	NOTES	 	REGISTERED
	 

	 	 	 	 	 	 	 	registered as of
July 08; waiting
for certificate	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	Chile

	 	Biomira Europe B.V.
	 	15/09/05
	 	750.683
	 	Certificate
received.
Trade-mark
protected until
February 14, 2016.

Priority claim not
reflected. Issue
being resolved.

A registered mark
must be shown with
the words “Marca
Registrada” or the
initials M.R. or ®
	 	Pharmaceutical and
veterinary
preparations.
	 
	 	 	 	 	 	 	 	 	 	 
	Colombia

	 	Biomira Europe B.V.
	 	15/09/05
	 	05-093-460
	 	Certificate
received.
Trade-mark
protected until May
5, 2016.

Must be used within
3 years of
registration to
avoid attack.
	 	Pharmaceutical and
veterinary
preparations.
	 
	 	 	 	 	 	 	 	 	 	 
	Ecuador

	 	Biomira Europe B.V.
	 	9/9/05
	 	161785
	 	Certificate
received.
Trade-mark
protected until
October 12, 2016
	 	productos
farmacéuticos,
veterinarios e
higiénicos;
sustancias
dietéticas para uso
médico, alimentos
para bebés;
emplastos, material
para curas
(apósitos)
materials para
empastar los

 

65

	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	STATUS AND	 	 
	COUNTRY/	 	 	 	FILING	 	FILING/REGISTRATION	 	SPECIAL	 	GOODS
	REGISTRAR	 	APPLICANT	 	DATE	 	NUMBER	 	NOTES	 	REGISTERED
	 

	 	 	 	 	 	 	 	 	 	dientes y para
moldes dentales;
desinfectantes;
productos para la
destrucción de
animales dañinos;
fungicidas,
herbicidas.

pharmaceutical,
veterinary and
sanitary products;
dietary substances
for medical use,
food for babies;
poultices, material
for priests
(dressings)
materials to fill
the teeth and for
dental molds;
disinfectant;
products for the
destruction of
harmful animals;
fungicides,
herbicides.
	 
	 	 	 	 	 	 	 	 	 	 
	Mexico

	 	Biomira B.V.
	 	19/9/05 (due to a
national holiday on
the
15th)
	 	918963
	 	Certificate
received.
Trade-mark
protected until
September 19, 2015.
	 	Pharmaceutical and
veterinary
preparations.
	 
	 	 	 	 	 	 	 	 	 	 
	Peru

	 	Biomira Europe B.V.
	 	09/09/05
	 	254054-2005
	 	Certificate
received.
Trade-mark
protected until May
5, 2016.
	 	Pharmaceutical
preparations and
veterinary
medicine.
	 
	 	 	 	 	 	 	 	 	 	 
	Venezuela

	 	Biomira Europe B.V.
	 	13/09/05
	 	20169-05

P-274381
	 	Cleared for
registration
October 25,
	 	Pharmaceutical and
veterinary
preparations.

 

 

66

	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	STATUS AND	 	 
	COUNTRY/	 	 	 	FILING	 	FILING/REGISTRATION	 	SPECIAL	 	GOODS
	REGISTRAR	 	APPLICANT	 	DATE	 	NUMBER	 	NOTES	 	REGISTERED
	 

	 	 	 	 	 	 	 	2006.
It may take up to
two years until the
registration
certificate is
issued.	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	Hong Kong

	 	Biomira Europe B.V.
	 	10/09/05
	 	300493092
	 	Certificate
received.
Trade-mark
protected until
September 9, 2015.

 — must be used
within 3 years or
can be attacked for
non-use

Name change to
Merck KGaA
recorded.
	 	Pharmaceutical and
veterinary
preparations.
	 
	 	 	 	 	 	 	 	 	 	 
	India

	 	Biomira Europe B.V.
	 	16/09/05
	 	1385353
	 	Filed. Objections
raised by
Trade-mark office
regarding
confusingly similar
names. It appears
to be routine
practice in India
for the Office to
raise an objection
to any application
that may be
remotely similar to
existing marks.
Local counsel has
filed compelling
objections to the
	 	Pharmaceutical and
veterinary
preparations.

 

67

	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	STATUS AND	 	 
	COUNTRY/	 	 	 	FILING	 	FILING/REGISTRATION	 	SPECIAL	 	GOODS
	REGISTRAR	 	APPLICANT	 	DATE	 	NUMBER	 	NOTES	 	REGISTERED
	 

	 	 	 	 	 	 	 	Examiner’s report
and are awaiting a
response.

February 19, 2008
— the application
has been published;
however, there are
significant errors
on the record and
local counsel has
been notified to
correct them.	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	Indonesia

	 	Biomira B.V.
	 	14/12/05
	 	D00.2005.019212
	 	Registered until
December 14, 2015
	 	Pharmaceutical and
veterinary
preparations.
	 
	 	 	 	 	 	 	 	 	 	 
	Israel

	 	Biomira B.V.
	 	7/09/05
	 	183510
	 	Registered until
September 7, 2015

Typographical
filing error to be
corrected by local
counsel.

Name change
recorded.
	 	Pharmaceutical
preparations for
the prevention and
treatment of
cancer.
	 
	 	 	 	 	 	 	 	 	 	 
	Lebanon

	 	Biomira BV
	 	13/09/05
	 	103793
	 	Certificate issued.
Protected until
September 13, 2020.

Name change
recorded.
	 	Pharmaceutical and
veterinary
preparations.
	 
	 	 	 	 	 	 	 	 	 	 
	Malaysia

	 	Biomira Europe B.V.
	 	09/09/05
	 	05015149
	 	Registered until
March 16, 2015.
Must use mark by
	 	Pharmaceutical and
veterinary
preparations.

 

 

68

	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	STATUS AND	 	 
	COUNTRY/	 	 	 	FILING	 	FILING/REGISTRATION	 	SPECIAL	 	GOODS
	REGISTRAR	 	APPLICANT	 	DATE	 	NUMBER	 	NOTES	 	REGISTERED
	 

	 	 	 	 	 	 	 	mark by
November 2010 at
the latest and mark
is subject to
cancellation if not
used during a three
year period.
	 	Certificate
received.
	 
	 	 	 	 	 	 	 	 	 	 
	Taiwan

	 	Biomira Europe B.V.
	 	08/09/05
	 	094043196
	 	Certificate issued.
Protected until
June 15, 2016.
Should be used
within 3 years of
registration.
	 	Pharmaceutical and
veterinary
preparations.
	 
	 	 	 	 	 	 	 	 	 	 
	U.A. Emirates

	 	Biomira Europe B.V.
	 	14/09/05
	 	73129
	 	Registered until
September 14, 2015
	 	Pharmaceutical
preparations and
veterinary.

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSIONexv4w4

Exhibit 4.4

FIRST AMENDMENT TO

AMENDED AND RESTATED RIGHTS AGREEMENT

     This Amendment to Amended and Restated Rights Agreement, effective as of May 14, 2009 (this
“Amendment”), is entered into by and between Trident Microsystems, Inc., a Delaware corporation
(the “Company”), and Mellon Investor Services LLC, a New Jersey limited liability company, as
rights agent (the “Rights Agent”).

     WHEREAS, the Company and the Rights Agent are parties to the Amended and Restated Rights
Agreement, dated as of July 23, 2008 (the “Rights Agreement”) (capitalized terms used herein but
not defined shall have the meanings ascribed to them in the Rights Agreement);

     WHEREAS, the Company (solely with respect to the joint and several undertaking on the
signature page thereto and Sections 3.4, 4.3, 4.6.2, 4.6.3(d), 6, 8.7, 8.8, 8.9, 11 and 13-20
thereto), and Trident Microsystems (Far East) Ltd., a wholly-owned subsidiary of the Company
(“TMFE”) have entered into Purchase Agreement, dated March 31, 2009 (the “Purchase Agreement”),
with Micronas Semiconductor Holding AG (“Micronas”), whereby TMFE and the Company will acquire
certain assets of Micronas and Micronas will receive shares of Common Stock and warrants to
purchase Common Stock of the Company (the “Acquisition”);

     WHEREAS, in connection with the Purchase Agreement, the Company will enter into a
Stockholder’s Agreement, dated May 14, 2009 (the “Stockholder Agreement”), with Micronas;

     WHEREAS, pursuant to Section 27 of the Rights Agreement, the Company may from time to time
supplement or amend the Rights Agreement, without the approval of the any holder of Rights, in
order to, among other things, make the provisions of the Rights Agreement inapplicable to a
particular transaction pursuant to which a person would otherwise become an Acquiring Person;

     WHEREAS, the Company desires to amend the Rights Agreement, on the terms set forth herein,
such that none of the Micronas Parties (as defined by the Stockholder Agreement) will become an
Acquiring Person, subject to such Micronas Party’s compliance with the terms of the Stockholder
Agreement; and

     WHEREAS, all acts and things necessary to make this Amendment a valid agreement according to
its terms have been done and performed, and the execution and delivery of this Amendment by the
Company and the Rights Agent have been in all respects authorized by the Company and the Rights
Agent.

     NOW, THEREFORE, in consideration of the premises and mutual agreements herein set forth, the
parties hereby agree as follows:

     Section 1. Amendment. Section 1(n) of the Rights Agreement shall be amended and
restated, as of immediately prior to the Effective Time (as defined in the Purchase Agreement), in
its entirety as follows:

 

 

     (n) “Exempt Person” shall mean, as the context may require, each, any and all of the
following:

     (i) the Company or any Subsidiary of the Company, including, without limitation, in
its fiduciary capacity, any employee benefit plan or employee or director stock plan of
the Company or of any Subsidiary of the Company, or any Person, organized, appointed,
established or holding Common Stock for or pursuant to the terms of any such plan or any
Person funding other employee benefits for employees of the Company or any Subsidiary of
the Company; and

     (ii) Micronas (as such term is defined in the Stockholder Agreement, dated May 14,
2009 between the Company, TMFE and Micronas Semiconductor Holding AG (the “Stockholder
Agreement”)), or any Affiliate of Micronas, who acquires shares of Common Stock (x) as
Consideration Shares or shares issuable upon exercise of the Warrants (as such terms are
defined in the Purchase Agreement) pursuant to the terms of the Purchase Agreement,
dated March 31, 2009 (the “Purchase Agreement”), by and between Micronas, the Company
(solely with respect to the joint and several undertaking on the signature page thereto
and Sections 3.4, 4.3, 4.6.2, 4.6.3(d), 6, 8.7, 8.8, 8.9, 11 and 13-20 thereto), and
Trident Microsystems (Far East) Ltd. (“TMFE”), or (y) subject to the limitations and
conditions set forth in the Stockholder Agreement, anytime thereafter, in each case, so
long as the aggregate amount of the “Beneficial Ownership” of “Equity Securities” held
by Micronas and any Affiliate does not exceed the “Applicable Percentage” (as such terms
are defined in the Stockholder Agreement); provided, that neither Micronas nor any
Affiliate of Micronas shall cease to be an Exempt Person (x) by reason of a purchase of
shares of Common Stock in excess of the Applicable Percentage to the extent such
purchase is in a Rights Offering (as defined in the Stockholder Agreement) or an offer
that was made generally available to holders of equity securities of the Company, or (y)
as a result of the exercise or exchange of Rights held by Micronas or an Affiliate of
Micronas or (z) by reason of an acquisition of shares made in compliance with the terms
and conditions of the Stockholder Agreement.

     Section 2. Governing Law. This Amendment shall be deemed to be a contract made under
the laws of the State of Delaware and for all purposes shall be governed by and construed in
accordance with the laws of such state applicable to contracts to be made solely by residents of
such state and performed entirely within such state; provided, however, that all provisions
regarding the rights, duties and obligations of the Rights Agent shall be governed by and construed
in accordance with the laws of the State of New York applicable to contracts made and to be
performed entirely within such state.

     Section 3. Counterparts. This Amendment may be executed in any number of counterparts
and each of such counterparts shall for all purposes be deemed to be an original, and all such
counterparts shall together constitute but one and the same instrument.

     Section 4. No Modification. Except as expressly set forth herein, this Amendment shall
not by implication or otherwise alter, modify, amend or in any way affect any of the terms,
conditions, obligations, covenants or agreements contained in the Rights Agreement, all of which

2

 

are ratified and affirmed in all respects and shall continue in full force and effect.
Without limiting the foregoing, the Rights Agent shall not be subject to, nor required to interpret
or comply with, or determine if any other Person has complied with, the Purchase Agreement or the
Stockholder Agreement, even though reference thereto may be made in this Amendment and the Rights
Agreement.

* * *

[Remainder of page intentionally left blank]

3

 

     IN WITNESS WHEREOF, the parties hereto have caused this First Amendment to Amended and
Restated Rights Agreement to be duly executed, and their seals affixed and attested, all as of May
14, 2009.

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[SEAL]	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	ATTEST:	 	 	 	TRIDENT MICROSYSTEMS, INC.	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	By:	 	/s/ DAVID L. TEICHMANN	 	 	 	By:	 	/s/ PETE J. MANGAN	 	 
	 	 	 	 	 	 	 	 	 	 	 
	 

	 	Name:
	 	David L. Teichmann
	 	 	 	 	 	Name:
	 	Pete J. Mangan	 	 
	 

	 	Title:
	 	Senior Vice
President, General Counsel
and Corporate Secretary
	 	 	 	 	 	Title:
	 	Chief Financial Officer	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[SEAL]	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	ATTEST:	 	 	 	MELLON INVESTOR SERVICES LLC,

as Rights Agent	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	By:	 	/s/ MARIA COOPER	 	 	 	By:	 	/s/ JOSHUA P. MCGINN	 	 
	 	 	 	 	 	 	 	 	 	 	 
	 

	 	Name:
	 	Maria Cooper
	 	 	 	 	 	Name:
	 	Joshua P. McGinn	 	 
	 

	 	Title:
	 	Relationship Manager
	 	 	 	 	 	Title:
	 	Senior Relationship Manager	 	 

4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00158-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00158-of-00352.parquet"}]]